Study Product Guidelines and Considerations  0 of 67 Version 3.0 
  12 August 2024   
 
 
 
 
  
Engaging Veterans Seeking Service -Connection 
Payments in Pain Treatment  
 
[STUDY_ID_REMOVED]   
 
8/12/24  
 
Study Protocol  
National Center for Complementary and Integrative Health  
      

Study Product Guidelines and Considerations  1 of 67 Version 1.1 
  27 April 2020  FULL PROTOCOL TITLE  
Engaging Veterans Seeking Service -Connection Payments in 
Pain Treatment  
  
Principal Investigator s:   
Marc Rosen, MD, Professor of Psychiatry, Yale Unive rsity; Director of 
Addiction Recovery Services , VA CT Healthcare System  
Steve Martino, PhD, Professor of Psychiatry, Yale U niversity; Chief of 
Psychology, VA CT Healthcare System  
Supported by:  
The National Center for Complementary and Integrative Health  (NCCIH) 
and The National Institute on Drug Abuse (NIDA)  
(NIH grant # UH3AT009758 ) 
 
Version 4.0 
 
Study Product Guidelines and Considerations  2 of 67 Version 1.1 
  27 April 2020  Tool Revision History  
Version Number: 1.0 
Version Date: 8/2/19  
Summary of Revisions Made: First Approved Version 
Version Number: 2.0 
Version Date: 4/27/20 
Summary of Revisions Made: Changes to protocol and questionnaires in response to COVID- 19 
pandemic  
Version Number: 3.0 
Version Date: 12/14/20  
Summary of Revisions Made: Adding prepaid incentive  and magnet to recruitment mailings to 
bolster recruitment and retention 
Version Number: 4  
Version Date: 8/12/24  
Summary of Revisions Made: Change to operationaliza tion of substance use outcome 
 
  
Study Product Guidelines and Considerations  3 of 67 Version 1.1 
  27 April 2020  TABLE OF CONTENTS  
Page  
FULL PROTOCOL TITLE  .......................................................................................................... 0  
Tool Revision History  ............................................................................................................... 2  
TABLE OF CONTENTS  ............................................................................................................. 3  
ABBREVIATIONS  ....................................................................................................................... 6  
STUDY TEAM ROSTER  ............................................................................................................. 9  
PARTICIPATING STUDY SITES  ............................................................................................ 10  
PRÉCIS  ........................................................................................................................................ 11  
1. STUDY OBJECTIVES  .......................................................................................................... 12  
1.1 Primary Objective  ....................................................................................................... 12  
1.2 Secondary Objectives  ................................................................................................ 12  
2. BACKGROUND AND RATIONALE ................................................................................... 12  
2.1 Background on Condition, Disease, or Other Primary Stu dy Focus  .................. 12  
2.2 Study Rationale  .......................................................................................................... 14  
3. STUDY DESIGN  .................................................................................................................... 18  
4. SELECTION AND ENROLLMENT OF PARTICIPANTS  ............................................... 23  
4.1 Inclusion Criteria  ......................................................................................................... 24  
4.2 Exclusion Criteria  ....................................................................................................... 24  
4.3 Study Enrollment Procedures ................................................................................... 24  
5. STUDY INTERVENTIONS  ................................................................................................... 27  
5.1 Interventions, Administration, and Duration  ........................................................... 27  
5.2 Handling of Study Interventions  ............................................................................... 31  
5.3 Concomitant Interventions  ........................................................................................ 31  
5.3.1  Allowed Interventions ............................................................................................... 31  
5.3.2  Required Interventions .............................................................................................. 31  
5.3.3  Prohibited Interventions ............................................................................................ 31  
5.4 SBIRT -PM Fidelity Assessment  ............................................................................... 31  
6. STUDY PROCEDURES  ....................................................................................................... 32  
6.1 Schedule of Evaluations  ............................................................................................ 32  
Study Product Guidelines and Considerations  4 of 67 Version 1.1 
  27 April 2020  6.2 Description of Evaluations  ........................................................................................ 33  
6.2.1  Screening Evaluation ................................................................................................ 33  
6.2.2  Enrollment, Baseline, and/or Randomization  ........................................................... 34  
6.2.3  Blinding..................................................................................................................... 40  
6.2.5  Completion/Final Evaluation  .................................................................................... 40  
7. SAFETY ASSESSMENTS  ................................................................................................... 41  
7.1 Specification of Safety Parameters  ......................................................................... 41  
7.2 Methods and Timing for Assessing, Recording, and Anal yzing Safety 
Parameters  .............................................................................................................................. 41  
7.3 Adverse Events and Serious Adverse Events  ....................................................... 42  
7.4 Reporting Procedures  ................................................................................................ 42  
7.5 Follow -up for Adverse Events  .................................................................................. 43  
7.6 Safety Monitoring  ....................................................................................................... 43  
8. INTERVENTION DISCONTINUATION  .............................................................................. 43  
9. STATISTICAL CONSIDERATIONS  ................................................................................... 44  
9.1 General Design Issues  .............................................................................................. 44  
9.2 Sample Size and Randomization  ............................................................................ 44  
9.3  Definition of Populations  ........................................................................................... 45  
9.4 Interim Analyses and Stopping Rules  ..................................................................... 46  
9.5 Outcomes  .................................................................................................................... 46  
9.5.1  Primary Outcome  ...................................................................................................... 46  
9.5.2  Secondary Outcomes  ................................................................................................ 46  
9.6 Data Analyses  ............................................................................................................. 47  
10.1  Data Collection Forms  ............................................................................................... 50  
10.2  Data Management  ...................................................................................................... 51  
10.3  Quality Assurance  ...................................................................................................... 51  
10.3.1  Training  ................................................................................................................. 51  
10.3.2  Quality Control Committee  ................................................................................... 52  
10.3.3  Metrics  .................................................................................................................. 52  
10.3.4  Protocol Deviations ............................................................................................... 53  
10.3.5  Monitoring ............................................................................................................ 53  
11. PARTICIPANT RIGHTS AND CONFIDENTIALITY  ...................................................... 54  
11.1  Institutional Review Board (IRB) Review  ................................................................ 54  
11.2  Informed Consent Forms  .......................................................................................... 55  
11.3  Participant Confidentiality  ......................................................................................... 55  
Study Product Guidelines and Considerations  5 of 67 Version 1.1 
  27 April 2020  11.4  Study Discontinuation  ................................................................................................ 57  
12. COMMITTEES  ..................................................................................................................... 58  
13. PUBLICATION OF RESEARCH FINDINGS  .................................................................. 58  
14. REFERENCES ..................................................................................................................... 58  
15. SUPPLEMENTS/APPENDICES  ....................................................................................... 67  
I. Informed Consent Form Template  ................................................................................... 67  
II. VA Central IRB reviewed and approved Protocol ( v.11/8/18)  .................................... 67  
 
Study Product Guidelines and Considerations  6 of 67 Version 1.1 
  27 April 2020  ABBREVIATIONS  
AE:    Adverse Event  
ASSIST:    Alcohol , Smoking and Substance  Involvement  Screening  
Test 
ATO:     Authorization to Operate  
AUDIT -C:   Alcohol Use Disorders Identification Test  
BPI:    Brief Pain Inventory  
C&P:     Compensation & Pension  
CAPRI:   Compensation and Pension Record Interchange  
CBT:   Cognitive Behavioral Therapy  
CDC:   Centers for Disease Control and Prevention  
CEACs:   Cost-Effectiveness Acceptability Curves  
CIDI:   Composite International Diagnostic Interview  
cIRB:   Central Institutional Review Board  
COVID -19  Coronavirus Disease 2019  
CPT:   Current Procedure Terminology  
CTSP:   Centralized Transcription Service Program  
DBQ:   Disability Benefits Questionnaire  
DSMC:   Data and Safety Monitoring Committee  
EHR:   Electronic Health Record  
ELISA:   Enzyme- Linked Immunosorbent Assay   
ETG:   Ethyl Glucuronide  
ETOH:   Alcohol  
EQ-5D-5L:  5 Level EuroQol: Instrument used to Describe and Va lue 
Health  
FDA:   Food and Drug Administration  
HERC:   Health Economics Resource Center  
HIPAA:   Health Insurance Portability and Accountability Act  
HSR&D:   Health Services Research & Development  
ICERs   Incremental Cost -Effectiveness Ratios  
IMMPACT:  Initiative on Methods, Measurement, and Pain Assessment  
in Clinical Trials  
IMPROVE:   Improving Pain -Related Outcomes for Veterans  
IRB:  Institutional Review Board  
ITRS:   Independent Tape Rater Scale  
ITT:  Intent to Treat  
JAMA:   Journal of the American Medical Association  
MAR:     Missing at Random  
MCAR:   Missing Completely at Random  
MCID:   Mean Clinically Important Difference  
MEDD:   Morphine Equivalent Daily Dose  
MI:  Motivational Interviewing  
MNAR:   Missing Not at Random  
mPI:  Multiple Principal Investigator  
MSD:   Musculoskeletal disorders  
NCCIH:   National Center of Complementary and Integrative Health  
Study Product Guidelines and Considerations  7 of 67 Version 1.1 
  27 April 2020  NDS:   National Data Systems  
NIDA:   National Institute on Drug Abuse  
NIH:  National Institutes of Health  
NLP:   Natural Language Processing  
NPCD:   National Patient Care Database  
NPM:   Non-Pharmacological Pain Modalities  
NRS:   Numeric Rating Scale  
OEF:   Operation Enduring Freedom  
OHRP:   Office for Human Research Protections  
OIF:  Operation Iraqi Freedom  
OI&T:   Office of Information & Technology  
PACT:   Patient Aligned Care  
PEG:   Three -Item Scale Assessing Overall Pain Intensity and 
Interference  
PMC3:  NIH-DoD-VA Pain Management Collaboratory Coordinating   
Center  
PHI:  Personal Health Information  
PHQ -9:  Patient Health Questionnaire  
PPV:   Positive Predictive Values  
PRC:   Protocol Review Committee  
PRIME:    Pain Research, Informatics, Multi- morbidities, and Education  
Center  
PT:  Physical Therapy  
PTSD:   Post-Traumatic Stress Disorder  
QUERI:   VA Quality Enhancement Research Initiative  
RCT:   Randomized Controlled Trial  
REDCap:   Research Electronic Data Capture   
SAE:   Serious Adverse Event  
SAMSHA:   Substance Abuse and Mental Health Services Administrat ion 
SBIRT:   Screening, Brief Intervention and Referral to Treatm ent 
SBIRT -PM  Screening, Brief Intervention and Referral to Treatm ent for 
Pain   
   Management  
SCAN -ECHO:   Specialty Care Access Networks -Extension for Community  
Healthcare Outcomes  
SPACE:   Strategies for Prescribing Analgesics Comparative 
Effectiveness  
SUD:   Substance Use Disorder  
SVM:   Support Vector Machine  
TAU:   Treatment -As-Usual  
TBI:   Traumatic Brain Injury  
TENS:   Transcutaneous Electrical Nerve Stimulation  
UG3:   Phase 1 Exploratory/Developmental Cooperative Agreeme nt  
activity code  
UGH:   Phase 2 Exploratory/Developmental Cooperative Agreeme nt  
   activity code  
Study Product Guidelines and Considerations  8 of 67 Version 1.1 
  27 April 2020  UC:  Usual Care  
VA:  Veterans Affairs  
VACHS:   VA Connecticut Healthcare System  
VACO:   VA Central Office  
VAMC:   VA Medical Centers  
VBA:   Veterans Benefits Administration  
VBMS:   Veterans Benefits Management Software  
VERA:   Veterans Equitable Resource Allocation  
Veterans’ Choice:   Veterans Access, Choice and Accountability Act  
VHA:   Veteran’s Health Administration  
VHA ORD:   Veterans Health Administration Office of Research and  
Development  
VINCI:   VA Informatics and Computing Infrastructure  
VISN:   Veterans Integrated Service Networks  
VPN:   Virtual Private Network  
VTT:   Visual Tagging Tool  
  
Study Product Guidelines and Considerations  9 of 67 Version 1.1 
  27 April 2020  STUDY TEAM ROSTER   
Marc Rosen, MD  (mPI), VA Connecticut Healthcare System, 950 Campbell Ave., West 
Haven, Connecticut, Tel: 203 -932-5711 x2112, Email: marc.rosen@yale.edu  
Steve Martino, PhD  (mPI), VA Connecticut Healthcare System, 950 Campbell Ave., 
West Haven, Connecticut, Tel: 203 -932-5711 x 7418 , Email: 
steve.martino@yale.edu ,  
William Becker, MD  (Co-Investigator), VA Connecticut Healthcare System, 950 
Campbell Ave., West Haven, Connecticut, Tel: 215-514-8006, Email: 
William.becker@yale.edu  
Brenda Fenton, PhD  (Co-Investigator), VA Connecticut Healthcare System, 950 
Campbell Ave., West Haven, Connecticut, Tel: 203 -932-5711 x 5174 , Email: 
Brenda.fenton@va.gov , VACHS  
John Sellinger, PhD  (Co-Investigator), VA Connecticut Healthcare System, 950 
Campbell Ave., West Haven, Connecticut, Tel: 203 -932-5711 x 3589 , Email: 
John.sellinger1@va.gov , Yale/VACHS  
Kristin Mattocks, PhD (Co- Investigator), Central Western Mass VA, 421 North Ma in St., 
Leeds, MA, Tel: 413 -584-4040 x2060, Email: Kristin.mattocks@va.gov  
Qing Zeng, PhD ( Co-Investigator), Washington DC VA Medical Center, 50 I rving St. 
NW, Washington DC, Tel: 203 -994-0477, Email: zengq@email.gwu.edu  
Tu Ngo , PhD (Site PI),  Bedford VA, 200 Springs Road, Bedford, MA, Tel: 781 -687-
2420, Email:  tu.ngo@va.gov  
Diana Higgins , PhD (Site PI), VA Boston, 940 Belmont St., Brockt on, MA, Tel: 857 -
3642221, Email: Diana.Higgins2@va.gov  
Bradley Brummett PhD (Site PI), Central Western Mas s VA, 421 North Main St., Leeds, 
MA, Tel: 413 -584-4040 x2489, Email: Bradley.brummett@va.gov  
Todd Stapley , DO (Site PI), VA Maine, 1 VA Ctr, Augusta, ME. Tel : 207 -623-8411 
x5384, Email: todd.stapley@va.gov  
Christina Zimmerman, DO (Site PI), VA Maine, 1 VA Ct r, Augusta, ME. Tel: 207 -623-
8411, Email: christina.zimmerman@va.gov  
Thomas Reznik, MD (Site PI), VA Providence, 830 Chal stone Ave, Providence, RI, Tel: 
401-273-7100, Email: Thomas.reznik@va.gov  
Alicia Semiatin,  PsyD (Site PI), Manchester VA, 718 Smyth Rd, Mancheste r, NH, Tel 
603-624-4366 x6588, Email: Alicia.semiatin@va.gov   
Paul Holtzheimer,  MD (Site PI), White River Junction VA, 215 North Mai n St., White 
River Junction, VT, Tel: 802 -295-9363 x5951, Email: 
paul.e.holtzheimer@hitchcock.org  
Christina Lazar, MPH (Project Director), VA Connecticut Healthcare System, 950 
Campbell Ave., West Haven, Connecticut, Tel: 203 -932-5711 x4833, Email: 
Christina.lazar@yale.edu  
Linda Adamczyk  (Research Assistant),  VA Connecticut Healthcare System, 950 
Campbell Ave., West Haven, Connecticut, Tel: 203 -932-5711 x3972, x 8124 , 
Email:  Linda.Adamzczyk@yale.edu   
Katarina Bernice (Research Coordinator), Bedford VA, 200 Springs Road, Bedford, MA, 
Tel: 781 -687-2420, Email:  Katarina.Bernice@va.gov  
Celia Butler (Research Coordinator), Providence VA,  830 Chalstone Ave, Providence, 
RI, Tel: 401 -273-7100, Email: celia.butler@va.gov   
Study Product Guidelines and Considerations  10 of 67  Version 1.1 
  27 April 2020  Rebecca Jankowski (Research Coordinator), Central West ern Mass VA, 421 North 
Main St., Leeds, MA, Tel: 413 -584-4040 x2069, Email: 
Rebecca.Jankowski@va.gov  
Laurie Waterman (Research Coordinator), White River Junction VA, 215 North Main St., 
White River Junction, VT, Tel: 802 -295-9363, Email: Laurie.Waterman@va.gov   
Cathy Lombardo (Research Coordinator), White River Ju nction VA, 215 North Main St., 
White River Junction, VT, Tel: 802 -295-9363, Email: Cathy.Lombardo@va.gov   
Kate Gilstad -Hayden (Biostatistician), 300 George Street, Departme nt of Psychiatry, 
Yale School of Medicine.  Tel: 203 -764-5973,  Email:  Kathryn.Gilstad -
Hayden@Yale.edu  
Paul Barnett, PhD (Collaborator), Palo Alto Veteran s Institute for Research, 591 Las 
Colindas Road, San Rafael, CA, Tel:  628 -240-3930, Email:  
Paul@Barnettfamily.org  
Yijun Shao, PhD (software developer), Washington DC VA Medical Center, 50 Irving St. 
NW, Washington DC, Tel: 203 -994-0477, Email: ychao@email.gwu.edu  
PARTICIPATING STUDY SITES  
Hub 
• Connecticut VA  
 
Spoke  
• Bedford VA  
• Boston VA  
• Central Western Massachusetts VA  
• Maine VA  
• Manchester VA  
• Providence VA  
• White River Junction VA  
Other  Sites Involved in Data Analysis   
• Washington DC VA  
  
  
  
Study Product Guidelines and Considerations  11 of 67  Version 1.1 
  27 April 2020  PRÉCIS  
Study Title  
Engaging Veterans Seeking Service -Connection Payments in Pain Treatment  
Objectives  
Determine the effectiveness and cost -effectiveness of Screening, Brief 
Intervention and Referral to Treatment for Pain Management (SBIRT -PM) 
compared to Usual Care (UC) in reducing pain and risky s ubstance use.  
Design and Outcomes   
In a pragmatic two -arm, parallel groups 36 -week multi -site randomized 
controlled single blind trial, we will randomize 1100 Veterans applying for 
compensation related to musculoskeletal disorders to ei ther SBIRT -PM or 
Usual Care (UC) across eight VA medical centers in New England.  
Outcome assessment by phone will occur at 12 - and 36 -week follow -ups and  
will be corroborated with other sources of informati on ---  the electronic health 
record and toxicology testing of nail clippings.   
Primary outcomes will be change in pain severity as measured by the Brief 
Pain Inventory ( BPI) and change in substances categorized as requiring 
intervention  measured by the ASSIST.  Secondary outcomes will incl ude non -
pharmacological pain management service utilization, NRS pain severity , pain 
interference with life activities  as measured by the BPI, overall pain (PEG) , 
overall health  (EQ-5D-5L), use severity for individual substances generated 
by the ASSIST, and toxicology results for individual su bstances. The trial will 
include cost -effectiveness and budget impact analyses.  
Interventions and Duration  
Screening, Brief Intervention and Referral to Treatment for Pain Management 
(SBIRT -PM) aims to engage Veterans applying for compensation  with pain 
conditions in multi -modal non -pharmacological pain care and to motivate 
those who misuse substances to change this problemati c behavior. SBIRT -
PM will be delivered centrally by telephone throughou t the New England VA 
Healthcare System’s (VISN1) eight medical centers. It involves an initial one -
hour session followed by up to three 20-minute calls in a 12 -week peri od and 
an additional call in the 12 -32 week period to support Veterans engagement 
in non -pharmacological pain care.  
Usual care (UC): A Veteran who completes a compensation examination 
ordinarily has no further treatment, referral or deb riefing as part of the 
Compensation  examination  
Sample Size and Population  
The study sample consists of 1100 randomized post -911 era Veterans 
applying for MSD related compensation. Participants wi ll be randomized 
using a computerized urn randomization program within  each site to increase 
the likelihood of balanced allocation of participant s to the two interventions on 
Study Product Guidelines and Considerations  12 of 67  Version 1.1 
  27 April 2020  sex, race, ethnicity and self -reported illicit drug use within 90 days.  
1. STUDY OBJECTIVES  
1.1 Primary Objective  
Our main objective is to test the effectiveness and cos t-effectiveness of SBIRT -PM, 
compared to UC, when delivered within a VISN1 -wide hub -and-spoke network.  
 Objective  1: We will determine if SBIRT -PM is more effective than UC in 
reducing pain severity as measured by the Pain Severity subscale of the BPI (primary 
outcome). Secondary outcomes include non -pharmacological pain management service 
utilization, pain interference with life activities  (BPI Interference Subscale ), and overall 
health .   Hypothesis : SBIRT -PM will be more effective than UC. We will test the  degree 
to which non -pharmacological pain management service utilization me diates pain 
outcomes.  
 Objective  2: We will evaluate if SBIRT -PM, compared to UC, is more effective in 
reducing the number of substances categorized as requiring any intervention as 
measured by the ASSIST (primary outcome).  Secondary o utcomes will include the use 
severity measure for individual substances generated by the ASSIST, and nail clipping 
toxicology results for individual substances.   Hypothesis : SBIRT -PM will be more 
effective than UC. We will separately test the degre e to which non -pharmacological pain 
management service utilization and substance use servic e utilization mediates the 
effect of SBIRT- PM on substance use outcomes.  
 Objective  3: We will assess the cost -effectiveness of SBIRT -PM relative to UC. 
Hypothesis : SBIRT -PM will be cost -effective relative to UC across a range of possible 
values of decision makers’ willingness -to-pay for minimal clinically important differences 
in pain severity  and interference .  
1.2 Secondary Objectives  
Our s econdary objective  is to determine if SBIRT -PM is more effect than UC in reducing 
overall pain as measured by the PEG , a common pain measure required across 
protocols funded by the NIH -DoD-VA Pain Management Collaboratory, which measures 
average pain intensity (P), interference with enjoym ent of life  (E), and interference with 
general activity (G) .  Hypothesis : SBIRT -PM will be more effective than UC.  
2. BACKGROUND AND RATIONALE  
2.1 Background on Condition, Disease, or Other Primary Study Focus  
Many Returning Post -9/11 Veterans Have MSD and Could Benefit from Non -
Pharmacologic Pain Care .  
 Military personnel carry heavy packs, move heavy equipme nt and undergo 
intense physical stresses; a high proportion of them will develop musculoskeletal 
disorders (MSD) involving chronic pain. Chronic pain is widely prevalent in Veterans 
and is one of the most common reasons for outpatient  healthcare utilization.1 In recent 
years, returning Operation Enduring Freedom (OEF) and  Operation Iraqi Freedom (OIF) 
post-9/11 Veterans with injuries have faced the prospect  of decades of chronic pain.2,3 
Study Product Guidelines and Considerations  13 of 67  Version 1.1 
  27 April 2020  By seven years after deployment, approximately 17.5% o f post -9/11 Veterans in VA 
treatment were diagnosed with back disorders and 17.0%  were diagnosed with joint 
conditions,4 higher rates than in comparable U.S. population coh orts.5 Back pain, 
followed by neck or joint pain, is the most common ca use of chronic non -cancer pain in 
Veterans.6  
 To decrease morbidity and mortality, a growing body o f research and expert 
consensus support a multi -modal pain treatment strategy.7,8 In this bio -psycho- socially -
oriented model, evidence -based non -pharmacologic treatment modalities are 
incorporated alongside pharmacologic treatment.9 Multiple studies have demonstrated 
the effectiveness of non -pharmacological pain management in improving chronic  pain 
outcomes, including, for example, physical therapy,10-12 cognitive behavioral 
therapy,13,14 yoga,15,16 and mindfulness based stress -reduction,17-19 and therefore 
guidelines now stress the importance of a multi -modal approach.7,20 In part to reduce 
prescribing of risky opioids, the availability of such mu lti-modal therapy at VA facilities 
was mandated by the 2013 Opioid Safety Initiative.21  
 
Veterans with MSD Are at High Risk for Substance Misus e and Need Early Intervention.  
Veterans22 and other people23 with painful MSD are at high risk for developing alcoh ol 
and other substance use disorders.24,25 Iatrogenic factors have contributed to the risk for 
substance use among Veterans. The opioids prescribed t o treat painful MSD carry the 
potential for aberrant use and eventually misuse. A r emarkably high proportion, 64%, of 
post-9/11 Veterans with chronic  non-cancer pain have been prescribed opioids,6 and 
Veterans prescribed opioids have worse outcomes than t hose not prescribed opioids.26 
The base rate of substance use disorders in post -9/11 cohorts is high,27-30 and baseline 
substance use is a risk factor for going on to use more  substances. The causality is 
bidirectional, in that substance use disorders predi spose people to incurring injuries,31 
and are overrepresented in Veterans with pain -related comorbidities27,32,33  
 Early intervention is needed for Veterans who have chro nic pain and are at risk 
for substance misuse or are already engaging in it. I ndividuals with chronic pain and 
SUD have worse pain -related outcomes34 and worse addiction -related outcomes,35 than 
those without comorbid pain, supporting the need to  intervene early to prevent this 
comorbidity. Restrictions on opioid prescribing may co me too late to alter the 
neurobiological changes associated with long -term opioid treatment for chronic pain.36-38 
These neuroplastic changes endure long after opioid treatment is withdrawn and are 
thought to play a key role in facilitation of trans ition to chronic pain. Early engagement of 
Veterans with chronic pain into multi -modal non -pharmacological treatments has  the 
potential to arrest the development of risky or disorde red substance use and help those 
already misusing substances to reduce or stop this p roblem behavior. Furthermore, 
since substance use is strongly associated with treatm ent non -compliance in numer ous 
settings, early interventions that reduce risky substance  use have the potential to 
improve pain treatment outcomes by increasing Vetera ns’ pain treatment adherence.  In 
this proposal, although measured separately from non -pharmacological pain treatmen ts, 
substance use treatment is facilitated because it is a c omponent of pain treatment.  
Study Product Guidelines and Considerations  14 of 67  Version 1.1 
  27 April 2020  2.2 Study Rationale  
Compensation Examinations as a Unique Opportunity to Engage Veterans in Multi -
modal Pain Care.  
As of 2015, there were 971,117 post -9/11 Veterans already receiving service -connected 
compensation. Many of these Veterans interact with s ervice -connection examiners at 
VA facilities, but they interact as claimants, not as patients. When Veterans end their  
military service, and begin the transition to civilian life, they are encouraged to file 
claims for physical or psychological conditions that may be related to their military 
service. Veterans are encouraged to file claims during demobilization, at Vetera ns’ 
resource fairs to publicize services available to Veterans , and at Veterans Service 
Organizations that offer assistance with the claims pr ocess.39 The claim is processed at 
the VA but does not involve clinical care.  
Many of these claims are for MSD. As of 2015, there w ere 559,999 post -9/11 
Veterans being compensated for back or neck condition s, and 596,250 for limitation of 
flexion in joints (Veterans often have more than one involved body part).40 In 2015 
alone, 313,052 new Veterans began receiving disabilit y compensation, of whom 
approximately 31% were under age 35.     
  Examinations to determine Veterans’ compensation are  important because: (1) 
they are often conducted when Veterans are in some degree of pain or crisis associated 
with their disorder; (2) significant financial remune ration is at stake; and (3) Veterans 
judged to have a service -connected condition will receive priority  care at the VA for it, 
typically for life. The compensation examiner has a re sponsibility to the agency that 
decides claims, the Veterans Benefits Administration ( VBA), to obtain information  so the 
claim can be adjudicated. Therefore, as in forensic ev aluations, compensation 
examiners are taught to tell Veterans that the purpo se of the examination is to evaluate 
the disability claim and not to provide treatment. Al though the examiner’s role might be 
complicated by him/her making a treatment recommendat ion, having another clinician 
explain available treatments is not. The failure to o ffer treatment can be alienating.41 
 Considerable public pressure has developed to improve  the process of 
evaluating compensation claims such that this process  includes approaches to engage 
Veterans in treatment. In testimony to the House Com mittee on Veterans Affairs, Linda 
Bilmes called for early intervention approaches that  interface with the compensation 
examination process for returning post -9/11 Veterans: “VBA should shift its focus away 
from claims processing and onto rehabilitating and r eintegration of Veterans.”42 
Congressional hearings in June 2011 addressed “Bridgi ng the Gap Between Care and 
Compensation for Veterans,”43 the very topic of this proposal. One of the witnesses 
cited our group’s editorial advocating engagement of Veterans in treatment when they 
apply for service -connection.44  
 
Motivational Interviewing to Engage Veterans with MSD  in Non -Pharmacological Pain 
Treatment .  
Motivational interviewing,45 a person -centered, brief psychotherapeutic approach, helps 
people resolve ambivalence toward positive behavioral change and strengthen their 
commitment to it.46 Multiple meta -analyses have shown that MI improves treatment 
outcomes across a variety of behavioral domains in bo th medical and non -medical 
settings, including for substance use and treatment engagement.47-49 MI can be 
Study Product Guidelines and Considerations  15 of 67  Version 1.1 
  27 April 2020  delivered in person or by telephone. Telephone -based MI has been used successfully to 
address substance use and other risky behaviors in a var iety of populations.50-56 It has 
been shown to significantly increase initiation and ret ention of post 9/11 veterans in both 
VA and non -VA mental health treatment, with a secondary effect of significantly and 
durably decreasing their marijuana use.57 
Notably, MI has been found to effectively improve chr onic pain treatment 
engagement and outcomes, especially when more than on e MI session is 
employed.58,59 Specifically, Habib et al59 found that a 2 -session assessment and 
feedback intervention based on MI, in comparison to a s tandard 2 -session assessment 
and educational control interview, significantly impro ved the rates in which patients with 
chronic pain attended a series of pain management wo rkshops. Similarly, Friedrich et 
al58 showed that patients with chronic low back pain attend ed more physical therapy 
sessions and had reduced disability and pain levels when  the physical therapists had 
been trained to use strategies consistent with MI dur ing the patients’ visits. MI is well -
aligned with expert recommendations for patient -centeredness and shared decision -
making in chronic pain management.60-63 Furthermore, the VHA National Center for 
Health Promotion and Disease Prevention has endorsed the use of MI “to elicit and 
increase Veterans’ own intrinsic motivation to partic ipate in healthcare decisions and 
change health behaviors that are key to improving heal th and maintaining their well -
being.”64 We propose to use MI to engage post -9/11 Veterans with MSD in multi -modal 
non-pharmacological pain management treatments. A recent meta -analysis of MI for 
chronic pain management concluded that MI is a promis ing approach for promoting 
engagement in treatments for chronic pain conditions and underscored the need for 
well-designed randomized controlled trials to determine th e effectiveness of MI within 
musculoskeletal health.65 
 
MI-based SBIRT for Pain Management to Engage Compensat ion-Seeking Veterans 
with Chronic Pain . 
SBIRT is an approach to identify and briefly intervene with patients with risky substance 
use in settings not typically associated with addiction  treatment.66,67 The Brief 
Intervention in SBIRT usually is based on MI. SBIRT is  efficacious for reducing 
unhealthy alcohol68,69 and tobacco use,70-72 although less well established for 
decreasing illicit drug use73,74 or improving drinking outcomes for people with seve re 
alcohol dependence.75,76 According to our pilot data, most Veterans meeting cr iteria for 
the proposed study are likely to have episodic risky drink ing rather than drug use and 
are not likely to have alcohol dependence (see Prelimi nary Studies section).  
  Our group developed SBIRT for Pain Management (SBIR T-PM) to promote 
engagement in multi -modal non -pharmacological pain management among 
compensation -seeking Veterans with chronic pain. In SBIRT -PM, a clinician meets with 
the Veteran after the compensatio n examination to address the presenting MSD 
complaint. A clinician rather than the compensation e xaminer delivers SBIRT -PM to 
allow the Veteran to engage in a confidential discussio n without concern about how it 
will impact the compensation claim. The clinician ad dresses Veterans’ motivation for 
multi -modal pain care, and explains how pain can be manag ed using a variety of non -
pharmacological pain management services. The clinicia n spells out how those services 
can be accessed at VA.  
Study Product Guidelines and Considerations  16 of 67  Version 1.1 
  27 April 2020    Using permissive language about how pain is commonly self -medicated with 
substances, the clinician transitions to inquiries ab out use of prescription and non -
prescription substances. The clinician then attempts to motivate Veterans to change 
their behavior if they are misusing substances. Thus , SBIRT -PM addresses the 
Veteran’s presenting pain complaint first and nascent  substance use subsequently.  
 
A Veterans Integrated Service Network Hub -and-Spoke Model of SBIRT -PM Delivery .  
The VA often employs the hub -and-spoke model to manage care across a 
geographically -dispersed healthcare system. The hub -and-spoke model allows for 
expertise concentrated in specific geographic areas t o be available throughout the 
system. The Veterans Health Administration is divided int o 18 geographical regions 
across the United States called Veterans Integrated Service Networks (VISN). VISNs 
are organized as hub -and-spoke networks in which a central administration oversees  
healthcare policy and service delivery of all medical cent ers in the designated region.77 
VISN 1 consists of eight VA medical centers and 50 outpa tient clinics throughout the six 
New England states.  
We will adopt a VISN1 -wide hub -and-spoke network implementation system in 
which VA Connecticut Healthcare System will serve as th e hub for SBIRT -PM delivery 
in all eight VISN1 medical centers. The hub will be t he site for screening and identifying 
individu als appropriate for SBIRT -PM, delivering the intervention via telephone to 
Veterans throughout New England, and referring Vete rans to site personnel who make 
pain management service referrals. This approach has t he advantage of fitting the way 
in which many other clinical interventions and areas o f expertise are delivered within 
VA. One widely used example of a hub -and-spoke model in VHA is SCAN -ECHO 
(Specialty Care Access Networks -Extension for Community Healthcare Outcomes). In 
these programs, “hubs” with  experts in a particular area arrange teleconferences,  
trainings, and case consultation for providers in “spo kes” or satellite sites. VA 
Connecticut is the site for a SCAN -ECHO program for pain management, and this 
model appears to be effective. Suggestive  evidence of its effectiveness is that providers 
who participate in the pain SCAN -ECHO program have been significantly more likely to 
use physical medicine, anti -depressants, and anti -convulsant treatments, but not 
opioids.78  Other examples are the VA Epilepsy Centers of Excellenc e to assure 
increased access to high quality of care for Veterans with epilepsy.79 A hub and spoke 
model has the advantage of being more cost -effective compared to no network from a 
hospital80 and societal perspective.81 Hub and spoke systems allow for full -time 
personnel to specialize in the intervention and serve multiple sites, rather than requiring 
training of larger numbers of personnel at many site s.  
  The theoretical framework for implementation of SBIRT -PM in a hub -and-spoke 
model is Relational Coordination.82 Relational Coordination refers to the quality of 
communication and collaboration across sites and is pr edictive of a team’s or 
organization’s ability to provide high quality care.83-85 Hub-and-spoke networks function 
through collaborative relationships between individuals  working across sites.86 
Information must flow effectively between members of t he hub -and-spoke sites for care 
to be timely, coordinated and appropriate for the pa tient. In this study, we will first 
explore how relationships among clinical and admini strative staff involved in pain care 
are coordinated at the sites during baseline semi -structured interviews early in the U G3 
Study Product Guidelines and Considerations  17 of 67  Version 1.1 
  27 April 2020  phase. Informed by what stakeholders tell us, we will  then work to build Relational 
Coordination within our hub -and-spoke network to deliver SBIRT -PM. 
Within the VA, there are financial incentives for VI SN-wide initiatives, such as the one 
proposed, that bring Veterans into VA care. The for mula for funding each VISN is 
essentially a capitated model of payment per Veteran,  called the Veterans Equitable 
Resource Allocation (VERA). Each additional patient in the New England VISN 
generates a mean of $650087 (the median is considerably lower) and Veterans whos e 
conditions are judged to be connected to their milita ry service are, understandably, the 
highest priority Veterans for VA facilities to enrol l. The VA as an organization depends 
on enrolling new Veterans as those from prior wars di e or move to other regions. 
Beyond having the potential to improve care for Vete rans applying for compensation for 
MSD -related claims, to the extent SBIRT -PM results in new Veteran enrollment, it could 
increase revenue into VISN1 and its medical centers. T herefore, our proposal includes 
a budget impact analysis, with the prosaic but crucial information as to how SBIRT -PM 
impacts the VISN bottom line.  We will determine the  cost and cost -effectiveness of 
SBIRT -PM because these data provide evidence for SBIRT -PM’s value.  
 
Study Product Guidelines and Considerations  18 of 67  Version 1.1 
  27 April 2020  3. STUDY DESIGN  
 
 
 
We will conduct  a pragmatic two -arm, parallel groups 36 -week multi -site randomized 
controlled single blind trial  of SBIRT -PM. Drawing from VISN1 medical centers, we will 
randomize 1100 post -911 era Veterans applying for MSD -related compensation to 
either: 1) SBIRT- PM, a single phone -delivered session followed by up to three calls in a 
12-week period  and an additional call in the 12 -32-week period; or 2) usual care (UC). 
Primary outcomes will be change in pain severity  (BPI Composite severity ) and change 
in the number of substance s categorized as requiring intervention  (ASSIST) .  The two 
primary outcomes will be measured by self -report at 12 - and 36 - week follow -ups.  The 
self-report  BPI and ASSIST measures  will be  completed with the Research Assistant by SBIRT -PM Study Design Overview  
Obtain list of Veterans applying for Service Connec tion for Back, Neck, Knee 
and/or Shoulder conditions at 8 Study Sites   
 
Recruitment letters mailed to Veterans who served P ost 911  
 
Follow -up battery of assessments  
administered between 12 -16 weeks after baseline  
Nail Sample  Research Assistant calls  Veterans to explain study. Potential subjects are 
screened with inclusion/exclusion criteria  within 6 weeks of letter mailing .  
 
Total N=1100: Obtain informed consent over the phon e (audio -recorded).  
Collect contact information and administer Baseline  battery of 
assessments. 4 days   
Randomize  
SBIRT -PM 
(4 phone sessions 
administered over 12 
weeks) n=550  No Additional 
Treatment  
n=550  
 Baseline   
Follow -up 1  
Follow -up battery of assessments  
administered between 36 -40 weeks after baseline  
Nail Sample  Follow -up 2  Prior to 
Enrollment   
EHR Data Collection  
Collect VA Staff Interviews and 
Survey Data Collection  
Analyze Study Data  End of 
Study  
Study Product Guidelines and Considerations  19 of 67  Version 1.1 
  27 April 2020  telephone with the patient’s responses entered direc tly into REDCap. The Research 
Assistant conducting all study assessments will be blinde d. Secondary outcomes will 
include non -pharmacological pain management service utilization, pa in interference with 
life activities  (BPI) , overall pain (PEG), overall health  (EQ-5D-5L), use severity for 
individual substances generated by the ASSIST, and toxicology results for individual 
substances. The trial will include cost -effectiveness and budget impact analyses.  
 
Study Settings .  
The study will occur within the eight VISN1 VA medical  centers (VAMC) located across 
six New England States. Each site provides MSD -related compensation examinations, 
addiction/mental health treatment, and a variety of n on-pharmacological pain 
treatments.  
 
The medical centers are:  
1. Bedford VAMC  
2. Boston Healthcare System  
3. Central Western Massachusetts  
4. Connecticut Healthcare System  
5. Maine Healthcare System  
6. Manchester VAMC  
7. Providence VAMC  
8. White River Junction VA  
 
Feasibility of Recruiting a Sufficient Number of Vete rans Who Meet Inclusion/Exclusion 
Criteria :  
As noted in the completed SBIRT -PM RCT, in only 21 months of recruiting, 1017 
examinations (for 1014 unique Veterans) were schedul ed for service -connection 
examinations for back, neck, knee, or shoulder. Over the 32 months of recruitment for 
the proposed study, this would come to 1448 potentia lly eligible Veterans at VA 
Connecticut. To  extrapolate from these values to the number of eligi ble participants we 
could expect at each of the other seven sites within VISN 1, we used VBA reports of 
new service -connec tion examinations requested at each of the other si tes for 
back/neck/knee/shoulder. We then assumed the same proport ion at each site would be 
eligible as were at the Connecticut site.  
At VA Connecticut, 257/1014 Veterans met eligibility  criteria and enrolled (a 
24.3% enrollment rate). The proposed study is likely t o enroll at least as high a 
percentage, and probably higher because: (1) enrollme nt by phone asks less of 
Veterans than enrollment in person required in the p rior study; and (2) there are fewer 
inclusion/exclusion criteria in the proposed study. C onservatively assuming the 18% 
enrollment rate in the UG3 pilot (with only one call  to many participants) yields 1862  
exceeding the s tudy’s randomization  goal of 1100 . The large sample allows for study 
completion should recruitment lag at one or more site s. 
The large numbers of readily recruitable Veterans in a single VISN speaks to 
how many Veteran are at risk and engageable at their service -connection examinations.  
  
Study Product Guidelines and Considerations  20 of 67  Version 1.1 
  27 April 2020  VISN 1 VA Medical Center Projected Number of Post -9/11 Veterans 
Scheduled for MSD Service -Connection 
Examination over 32 Months of Study  
VA Boston  2478  
VA Connecticut  1448  
Providence, RI  1584  
Manchester, NH  1275  
Togus, ME  1493  
Bedford, MA  744 
White River Junction, VT  677 
VA Central Western Massachusetts HCS  650 
Total  10349  
 
Sources of Materials  
 
Veterans sources of materials : 
Information to be collected includes:  
1. Veteran questionnaire responses entered into VA RED Cap 
2. Nail clipping toxicology tests  
3. Audio recorded SBIRT -PM sessions  
4. Information from the electronic health record (EHR),  including the record of 
the Compensation examinations and service connection determination  
5. Service use data from central VA databases  
 
VA Staff sources of materials : 
Information to be collected includes:  
1. Responses to Relational Coordination Survey  
2. Digital recordings of interviews and transcriptions  
 
Assessment Procedures .  
A research assistant, blind to study condition, will conduct baseline, 12 - and 36 -week 
participant assessments by telephone. Veterans will be  instructed during the 
assessments not to tell the research assistant if they ar e receiving study counseling. To 
determine if the blind was maintained, the research as sistant will be asked in what 
condition each Veteran was assigned. In the initial RCT of SBIRT -PM reported in the 
Preliminary Studies, the accuracy of research assistants ’ guesses about  treatment 
condition assign ment  were almost exactly at chance (52%).  We will abstrac t data from 
the VA electronic health record (EHR) when possible.  
 
Procedures to Collect Self -Report Data from Veteran Participants .  
The self -reported assessment will be conducted by phone. Baseli ne assessment will be 
conducted as soon as possible after enrollment, and fo llow-up phone assessments will 
be conducted approximately 12 and 36 weeks after ran domization. Participants will 
receive a reminder call or text/email message prior to s tudy appointments (e.g. , “your 
follow -up phone interview with our research study is Monday, December 11th at 1:30. 
Please call [Name] at xxx -xxx- xxxx if you need to reschedule” ). If a participant misses a  
scheduled appointment, the research assistant will call to reschedule. Participants will 
be asked at the beginning of enrollment for the name s and telephone numbers of three 
Study Product Guidelines and Considerations  21 of 67  Version 1.1 
  27 April 2020  people who can find them if the research assistant has difficulty reaching them. These 
people will be contacted if the research team is unabl e to reach the Veteran within a 
three -week period.  
 
Procedures to Collect Self -Report Data from VA Staff Participants  
Each Site -PI will identify a list of 7 -10 stakeholders (providers in primary care clinics, 
pain service clinics, administration, and Compensation  & Pension clinics) at their site. At 
the end of the study (after recruitment and follow -up appointments are complete), our 
qualitative expert and her team will contact stakeho lders by email, inviting them to 
participate in a semi -structured interview designed to better understand how  pain 
services are conducted at their site and how staff at e ach site  communicate with other 
clinics regarding Veteran referrals for pain services. The qualitative expert and her team 
will place a follow -up phone call to stakeholders to schedule an interview . Interviews will 
last approximately 30 minutes, and will utilize a se mi-structu red interview guide. 
Interview responses will be audio -recorded and professionally transcribed by a VA 
approved transcription service for later qualitative ana lysis.  
 Stakeholders will also be invited via email to comple te a Relational Coordination 
survey, administered through VA REDCap. Survey response s will be collected 
confidentially and stored in VA REDCap in the secure V A environment.  
 
Procedures to Collect Data from the VA Electronic He alth Record .  
VHA databases in the Corporate Data Warehouse hold patient demographics, 
diagnoses, and encounter information from all Veter ans who have received services 
from anywhere in VHA. Veterans who are scheduled for  a service -connection 
examination (all study participants) have a medical r ecord with VHA. The encounters 
indicate a provider, service provider, diagnoses addr essed, and clinic in which services 
were delivered (e.g. mental health, substance use, primary care, pain clinic). The 
diagnosis and service -use data are not comprehensive for Veterans who have not been 
receiving their care at VA, but positive findings suc h as treatment encounters and 
diagnoses reflect clinical care/evaluations and thei r charting by providers.  
 
Costs Estimation Procedures .  
We will use the customized Resource Allocation Worksheet  to estimate the costs of 
delivering SBIRT -PM from the perspective of the providers (i.e., both t he VISN and 
hospital).  Cost estimation for VA services used by Veterans duri ng the 36 -week study 
period will be assessed using national VA administrati ve databases. Data on service 
use at the individual patient level will come from t he VA National Patient Care Database 
(NPCD), w hich includes information on all inpatient and outpa tient encounters at VA 
facilities. Costs for these services will be computed u sing the VA Average Cost 
Database, developed by the Health Economics Resource Ce nter (HERC). The Average 
Cost Database assigns an average cost to each inpatien t admission and outpatient visit 
in VA. Costs are based on Current Procedure Terminol ogy (CPT)  codes and can be 
linked to unique records in the NPCD.  
 Costs for VA services used by Veterans during the 36 -week study period will be 
assessed using national VA administrative databases. Dat a on VA service use at the 
individual patient level will come from the VA Nati onal Patient Care Database (NPCD), 
Study Product Guidelines and Considerations  22 of 67  Version 1.1 
  27 April 2020  which includes information on all inpatient and outp atient encounters at VA facilities. 
Costs for these services will be computed using the VA  Average Cost Database, 
developed by the Health Economics Resource Center (HE RC). The Average Cost 
Database assigns an average cost to each inpatient admi ssion and outpatient visit in 
VA. Costs are based on Current Procedure Terminolog y (CPT) codes and can be linked 
to unique records in the NPCD.   Costs incurred by VA for community care will be 
obtained from databases  tracking payments to community providers.  
 
Procedures to develop a new natural language proces sing (NLP) algorithm that 
identifies use of non -pharmacological pain management services  
To comprehensively identify pain -related treatment delivered to study participants, we  
will validate and extend existing natural language sea rch algorithms, using previously -
described procedures, to identify current use of a co mprehensive set of pain treat ments 
including those not covered by the existing algorithms . Those modalities will be drawn 
from a review of modalities used by Veterans for pa in treatment and those offered in 
VISN 1. Algorithm development will be informed by o ur prior experience with th is study 
design. We will design algorithms to maximize positi ve predictive value (at the expense 
of sensitivity) to avoid the risk of including false pos itives that are not randomly 
distributed (e.g., refused treatment referrals). The NLP extraction target  will be current 
use of the modality. Particular attention will be pai d to excluding pain discussions that 
do not represent treatment because they were obtain ed in the course of routine medical 
history reviews. Algorithm development involves extract ing relevant snippets that 
mention a particular pain treatment, establishing a v alid classification system for current 
use of that pain treatment, and optimizing the machi ne learning algorithm to identify 
current use of that treatment.  
Extracting relevant snippets: In brief, terms related  to each of the pain treatments 
(i.e. therapy keywords) will be generated by the inv estigative team. For example, for 
physical therapy, terms might include “physical therapy ,” “PT,” or “physical therapist.” A 
simple algorithm will identify these terms, along with the 10 preceding an d 10 following 
words. By our observation, a 20 -word window is sufficient to capture most of the 
relevant context, and also allows for fast review of  multiple records. The algor ithm will 
be modified using Boolean terms (e.g. physical NOT ph ysical exam). We will refine the 
search terms and extract 20+ word snippets using the Vo ogo clinical data search 
engine.  
Establishing a valid classification system for use of a pain treatment modality : 
The investigators  will develop annotation guidelines for classifying sn ippets as 
representing current service use (e.g. of physical ther apy services as no/yes/probably). 
One challenge is that the documentation of temporal i nformation varies in specificity. 
We will classify  the temporal information into several categories ba sed on the onset and 
duration attributes. For instance, usage with a non -specific past start and end time (e.g. 
“patient used physical therapy before”) will be consid ered to be past usage, usage with 
no specific past start but no end time (e.g. “patien t has been going to a physical 
therapist”) will be considered current for the time of documentation, usage with specific 
start and end time will be considered current for th e time it specified, etc. The 
annotation guidelines will be revised and then teste d on 100 snippet samples until a 
kappa of 0. 75 is reached between the two experts.  
Study Product Guidelines and Considerations  23 of 67  Version 1.1 
  27 April 2020  Optimizing the machine learning algorithm to identi fy use of a pain treatment: We 
will then randomly select 500 text snippets containin g terms per type of pain therapy 
from all retrieved notes from primary care and perfo rm human review based on the 
annotation guideline described above. Annotation wor k will be carried out using the 
Visual Tagging Tool (VTT). This set of annotates data  will be added to our existing set 
of annotated data (n=3000) and serve as the new gold/ reference standard for machine 
learnin g and training. We will apply a machine learning alg orithm, Support Vector 
Machine (SVM), to identify current use of pain thera py, optimizing for highest positive 
predictive values (PPV). Informed by our prior experi ence, we will use therapy 
keywords, n gram (n consecutive words), note type, and  temporal information as 
features in the classification of current use. Tempo ral information will be extracted using 
a prior method developed and tested by Dr. Zeng.88  
To assess the NLP performance, we will perform 10 -fold cross validation, which 
partitions the entire annotated sample into 10 rand om sets with equal size, uses 9 sets 
for training and 1 for testing, and repeats 10 times.  Our target PPV is >=90%, which is 
very likely to be reachable  because : 1) the specificity of the test has been set  high (at the 
cost of sensitivity ); 2) the usage level (prevalence) of the primary non-pharmacologic 
modalities for chronic pain treatment is high which  increases PPV; 3) we achieved 89% PPV in 
our work on a small set of modalities. We will apply machine learning methods we trained 
using previously acquired annotated data such as Sup port Vector Machine and Random 
Forest, and will use an ensemble learning step call ed Stacking,89 in which a learning 
algorithm combines the results of several other lear ning algorithms, if the separate 
programs’ performance fails to reach the target posi tive predictive value.   In the unlikely 
event that the PPV is not reached for a particular CI H modality, that modality’s 
assessment will be conducted by the other two availab le methods (self -report and EHR 
codes).  
 
 
4. SELECTION AND ENROLLMENT OF PARTICIPANTS  
 
For this pragmatic clinical trial, the study inclusio n and exclusion criteria are broad.  
There are no specific evaluations of capacity to consen t or complete study procedures.   
 Participants must meet all the inclusion criteria to participate in this study.  
Consistent with the guidelines for pragmatic trials,  we have taken a broad perspective to 
include all participants who have MSD -related conditions with moderately severe pain, 
regardless of the type of MSD, their anticipated respo nsiveness to SBIRT -PM, or 
psychiatric, substance use, or medical comorbidities  or past compliance. Because 
SBIRT -PM targets pain, and is telephone -based, at baseline participants must self -
report moderate pain severity and have access to a te lephone to test the effectiveness 
of the SBIRT -PM in this clinical trial. The other targeted outcome , substance use, is not 
an inclusion criterion. But rates of risky use in the  completed RCT were high enough for 
an adequately -powered study without requiring baseline use as an i nclusion criterion.  
 Candidates meeting any of the exclusion criteria at ba seline will be excluded 
from study participation.  We are excluding people who are already connected t o three 
or more VA nonpharmacological pain to minimize a ceil ing effect, i.e., such participants 
have a lower likelihood of needing a referral.  
 
Study Product Guidelines and Considerations  24 of 67  Version 1.1 
  27 April 2020  4.1 Inclusion Criteria  
 
1. post-9/11 Veteran applying for MSD -related compensation  (specified as back, 
neck, shoulder, or knee pain), as ascertained from fi led claim,  
 
2. reports a score of ≥4 (threshold for moderately severe pain) on the BPI’s Pain 
Severity subscale (average of four pain intensity ite ms);  
 
3. availability of a landline or cellular telephone for  SBIRT -PM.  
 
4.2 Exclusion  Criteria  
 
1. reports inability to participate during the study enr ollment call;  
 
2. received three or more non -pharmacological pain treatment modalities within th e 
last 12 weeks from VA  (modalities are: (1)  acupuncture (2) rehabilitation 
therapies  (3) Manipulation (4) Massage (5) Yoga (6) Tai Chi/Q igong (7) exercise 
(8) Biofeedback (9) Hypnosis/Hypnotherapy (10) Guided I magery (11) Meditation 
(12) Psychotherapy/Counseling (13) Reiki (14) teaching about coping with pain  
(15) other treatment for pain);  
 
3. participation in another PMC3 study as evidenced by a  research protocol alert for 
that study at the time the study invitation letter is mailed.  
  
4.3 Study Enrollment Procedures   
Human Subjects Involvement. The proposed project will  include two groups of human 
subjects, (1) Veterans and (2) VA staff (clinicians an d administrators).  
 
Screening and Recruitment for Veterans .  
A waiver of Informed Consent and a waiver of HIPAA Au thorization were  obtained to 
review the Compensation and Pension Clinic’s schedule  to determine when a MSD 
examination is scheduled for a post -9/11 Veteran. The waiver allow s for the collection of 
basic demographic information concerning Veterans scre ened for study participation to 
determine if Veterans who consent to study participa tion differ systematically from those 
who do not. The proposed study will employ recruitm ent procedures used in 
Compensation  Clinic -based studies by our group. There have been no advers e events 
associated with these recruitment procedures.  
The recruitment strategy involves first identifying Ve terans scheduled for a 
compensation examination for a MSD by reviewing char t and Compensation Clinic 
information about Veterans scheduled for these evalu ations. A research assistant at the 
hub site will  exclude people whose records preclude post -9/11 military service and mail 
recruitment letters. These potentially eligible Vetera ns will be mailed a letter from the 
Study Product Guidelines and Considerations  25 of 67  Version 1.1 
  27 April 2020  research team  explaining the basics of the study and that unless the Veteran opts out, a 
member of the research team will call to further ex plain the study. A toll -free phone 
number will be included in the letter that Veterans  can call to opt out of receiving the 
phone call or to express their interest in participating.  A magnet with study contact 
information and $1 USD will be included with the rec ruitment letter. All veterans who are 
identified as a potential participant and mailed a r ecruitment letter will receive the  
magnet and dollar regardless of whether or not they choose to enroll in the study. The 
magnet is a non -monetary incentive (valued at approximately $0.21) tha t will increase 
response rate, as potential participants can post the  magnet in an easy to see loc ation 
to remind them that the study personnel will be call ing. It might also help with retention 
rates for enrolled participants as it can be a visual r eminder of participation and the 
study team contact information will be readily avail able. The dollar is  a monetary 
incentive designed to increase the rate at which peo ple will take the study team call. 
One year into the study, we have found that we are unable to contact 45% of people 
who are mailed a letter after three contact attempt s. Research has shown that pre -paid 
incentives are most effective at increasing response  rate. However, the value of the 
incentive is nominal so as not to be coercive or to cr eate an undue influence on people 
from a lower socioeconomic class.  
Veterans who opt out will not receive any more study -related phone calls. A copy 
of the Study Information Sheet describing the study w ill be included with the recruitment 
letter.  
At least four days after the recruitment letter is se nt, resear ch assistants will 
attempt to call Veterans up to three times to invite them to pa rticipate in the study. A 
four-day waiting period from the day the letter is mailed to  the day of the call is sufficient 
to allow Veterans time to receive the letter in the mail and opt out if preferred . At that 
call, the research assistant will explain the study and  further screen for eligibility. For 
eligible Veterans, the research assistant will conduct informed  consent followed by  
baseline assessments during this phone call or subseque ntly. Although enrollment 
ideally occurs before the Compensation examination, Veterans will be allowed to enroll 
up to six weeks after  recruitment letters are mailed .  If a Veteran misplaces or has not 
received the Study Information Sheet, the Research As sistants will offer to mail another 
copy to the Veteran. The Veteran can choose to conti nue with the recruitment call or to 
wait until they receive the copy of the Information Sheet before continuing.  
 
Informed Consent and Enrollment for Veterans:  
Voluntary informed consent will be obtained from all  Veterans prior to participation. A 
waiver of Documentation of Informed Consent and a wa iver of HIPAA Authorization has 
been  obtained  for this study .  
Participants will receive a Study Information Sheet d etailing the study. In an 
audio -recorded telephone call, a research assistant will go over all aspects of informed 
consent with potential participants. At the start of the call, the research assistant wi ll 
verify the identity of the participant. Veterans will be  provided with information about the 
SBIRT -PM intervention, how long it will last, the nature of study assessments, 
information  about the collection of biological specimens, the exa mination of thei r 
electronic health care and VA data, and potential ri sks and benefits of study 
participation. Veterans will be reminded that they c an withdraw from the study at any 
Study Product Guidelines and Considerations  26 of 67  Version 1.1 
  27 April 2020  time without penalty. They will be given the opportun ity to ask questions and then will be 
asked if they agree to participate.  
Veterans who agree to participat e will state so for the audio -recording. Audio -
recorded consents will be stored in a restricted rese arch investigator folde r on VA 
Network computers behind the VHA firewall.  Only research staff will have access to the 
recordings.  
Staff obtaining verbal consent will have completed a web -based course with 
post-test on Human Research Protections, and all will hav e had specific training by the 
mPIs in obtaining informed consent for this project. All staff obtaining consent will be 
authorized to do so by the VA Central IRB.  
Justification for obtaining a waiver of documentation of informed con sent and 
waiver of HIPAA Authorization : These waivers are necessary to conduct the study. The 
purpose of this study is to test the usefulness of re motely delivered counseling. All 
counseling sessions and research assessments are conducted  remotely. There is no 
face-to-face contact with participants and the study is consid ered minimal risk. It would 
be burdensome and impractica l to have potential participants come in to the VA jus t to 
sign a study Consent Form and HIPAA authorization. Thi s study could not practicably 
be conducted without the waivers due to the timing of  study procedures. Baseline 
assessments and study counseling should occur before or w ithin six weeks after the 
recruitment letter is mailed. Waiting for the Vetera n to find time to come to the VA to 
sign a Consent Form and HIPAA Authorization or waiting  for the Veteran to return a 
signed copy of the Consent Form and HIPAA Authorizati on by mail will likely push the 
timing of study assessments outside of this window, maki ng a large proportion of 
eligible Veterans ineligible.  
Randomization : The unit of randomization is participant.  Participants will be 
randomized to SBIRT or Usual Care using a computeri zed urn randomization program90 
within each site to increase the likelihood of bala nced allocation of participants to the 
two interventions on sex, race (Caucasian, African American), ethnicity (Hispani c 
no/yes) and self -reported illicit drug use within 90 days. The resea rch assistant will be 
blind to the assigned condition.  For each participant, Research Assistants will 
communicate data needed for the urn to the Project Director , who will randomize the 
participant and assign a study therapist based on loca tion, availability and work flow.  
Enrollment : Participants are considered enrolled after they compl ete the informed 
consent process and agree to study procedures.  
 
Informed Consent and Enrollment for VA Staff:  
A waiver of documentation of Informed Consent for VA S taff participants has been  
obtained  for staff participants .  
 Research staff will describe the purpose of the surv ey and interview prior to 
administering these assessments. Participating VA staf f members will be encouraged to 
ask any questions and have the option to discontinue part icipation without prejudice. 
They will be approached by people other than their direct supervisors.  
 After a brief reiteration of the study purpose, the  interviewer will confirm consent 
to record the interview for transcription and analysis p urposes before proceeding.  
 
Study Product Guidelines and Considerations  27 of 67  Version 1.1 
  27 April 2020  Screening for medical record review to develop the na tural language processing (NLP) 
algorithm for pain -related treatments .  
A computer algorithm will be used to identify key ter ms (e.g. “physical therapy” along 
with the 10 preceding and 10 following words: a snip pet. Snippets of chart data will be 
identified that contain pain -related treatment keywords and surrounding text will  be 
identified from electronic medical records from up to  10,000,000 (approximately number 
of Veterans with medical records). As such, although not specifically queried for PHI, a 
snippet might contain some PHI such as a visit date a nd doctor’s name.  All of the work 
with the snippets is done in the VINCI data analysis env ironment behind the firewall in 
the VA. Access to the VA network and VINCI are passwor d protected and only 
accessible at the VA or through remote access with an approved device. These 
snippets will be reviewed to identify approximately 70 0 snippets per pain treatment 
modality (100 for developing annotation and 600 for  validating the algorithm using the 
developed annotation).  
5. STUDY INTERVENTIONS  
5.1 Interventions, Administration, and Duration   
SBIRT -PM Intervention.  
SBIRT -PM involves a  manualized, motivational interviewing -based  4-session telephone -
delivered intervention over  a 12-week period to motivate  Veteran s to engage in multi -
modal non -pharmacological pain care and , for those with co -occurring risky  substance  
use, also  change this problematic behavior. SBIRT -PM also includes coordination 
between the SBIRT -PM counselors  and the PACT nurse case manager or primary care 
provider after the initial session to support these patient o utcomes. SBIRT -PM will be 
delivered centrally from the VA  Connecticut hub to the VISN1 medical centers by 
counselors  trained in the approach. All sessions will be audio recorded for the purposes 
of SBIRT -PM fidelity assessment and supervision.  
 
Initial Session .  
The initial session is conducted after the compensatio n examination for the presenting 
MSD complaint . The counselor begins by  explain ing the separation between any 
service- connection claim and the counseling, as we have done in prior studies. The 
counselor also explains the structure (4 sessions over 1 2 weeks), and focus 
(engagement in pain management services, changing ris ky substance use if it exists) of 
SBIRT -PM and then begins the interview by asking about the Veteran ’s MSD condition 
and experiences with pain , conveying understanding and compassion for the Veteran’ s 
experience.  Next, the counselor explains how pain can be managed using a variety of 
pain management services , and how these services can be accessed at VA . 
 The counselor explains pain management consistent with  guidelines issued by 
the American College of Physicians,91 calling for education, encouragement of self -
management, and judicious use of non -opioid medications. The explanation is in the 
spirit of providing information, not an exhortation. The counselor describes how the goal 
of pain treatment is improving function (“helping you  get back to doing things that are 
important to you”) and that it may take a variety of  different treatments to achieve this 
Study Product Guidelines and Considerations  28 of 67  Version 1.1 
  27 April 2020  goal. The counselor further describes how pain is com monly associated with decreased 
activity, which in turn can contribute to other probl ems.  
 The counselor’s explanation of the role of opioid med ications paraphrases 
messages that primary care providers deliver to Vetera ns as part of Dr. Becker’s safe 
prescribing approach.92 The counselor explains that medications, including bo th opioid 
and non -opioid medicines, have an important place in some V eterans’ pain treatment, 
and that Veterans benefit when pain medicines are p rescribed and taken safely. The 
counselor reinforces the importance of taking opioid medicines as prescribed because 
there are risks of addiction and interactions with othe r substances (like alcohol). The 
counselor explains that judicious use of non -opioid medications improves pain treatment 
outcomes without the se risks.  
 The counselor introduces the idea that non -pharmacological treatments can help 
manage pain, and explains what they are and how the y work. These services may 
include: (1) treatment for the underlying ailment, ( 2) physical therapy (both at VA and as 
home exercise and stretching programs), (3) behavioral t reatments like Cognitive 
Behavioral Therapy for chronic pain, (4) treatments f or depression, PTSD, and/or other 
mental health problems that chronic pain may have aggr avated, and (5) complementary 
and integrative health interventions available includi ng chiropractor services, 
acupuncture and yoga.  
 Throughout these discussions, the counselor seeks oppo rtunities to motivate the 
Veteran to engage  in multi -modal pain care  using a variety of MI consistent approaches.  
If the Veteran commits to engaging in pain manageme nt services, the counselor 
develops a plan with the Veteran to initiate this pr ocess. For Veterans not enrolled in VA 
services, the counselor  explain s the procedures to obtain eligibility for VA care.  
• After motivating Veterans for engagement in pain man agement services, the 
counselor transitions to screening for substance use.  The coun selor explain s that 
some people with chronic pain use various substances to help them cope with the 
pain, and obtains  the Veteran’s permission to discuss this. The counselor then 
screens for substance use.  If the Veteran reports no risky substance use, the 
counselor summarized the session, reiterates the plan, and schedules the next 
session.  If the Veteran reports risky substance use, the  counselor asks more about 
it and how the use is affected by the Veteran’s pain.  The counselor provides 
feedback about the risky substance use, including  evidence that people who don’t 
misuse substances  have significant reductions in their pain compared t o those who 
continue to do so .  As with efforts to address the Veteran’s interest in p ain 
management services, the counselor uses MI consistent approaches to motivate the 
Veteran to stop or reduce risky substance use. Some Vet erans will not want to 
pursue abstinence and, for them, a harm reduction ap proach will be taken, meaning 
the counselor  and Veteran will negotiate a plan to use less  of the problematic 
substance per occasion, or use on fewer days, but not necessarily strive for 
abstinence. The counselor will develop a plan with the Veteran ab out how to reach a 
goal of abstinence or reduced or less frequent use, including options for engaging in 
specialty addiction treatment services available at the VA. When mental health 
issues further complicate the Veteran’s pain managemen t and risky substance use, 
the counselor will also discuss these issues with the Ve teran.  In fact, some 
Veteran s may insist on PTSD (or depression) treatment instead of substance abuse 
Study Product Guidelines and Considerations  29 of 67  Version 1.1 
  27 April 2020  treatment, and, consistent with MI, Veterans will r eceive information about preferred 
available treatments, including if the Veteran pref ers to first talk with the primary care 
provider about his or her addiction or mental health concerns .   
  
Follow -up Sessions . 
After the initial session, the counselor  will have up to three 20 -minute, mutually 
scheduled phone counseling sessions  with the Veteran (about once per month for 12 
weeks) to check on the Veteran’s status in achieving t he goals of the plan, and to gauge 
his or her continued motivation to receive pain trea tment and reduce risky substance 
use, as indicated. An additional call during the 12 -32-week period is permissible to re -
motivate veterans to engage in available pain and subst ance use services in view of 
any healthcare system changes that occurred (see respons e to COVID -19 section 
below). These calls may be informed by information the counselor  has obtained from 
the PACT providers or information in the electronic health rec ord (e.g., seeing if a 
consult was placed, reviewing progress notes indicating  engagement with services ). 
Twelve weeks allows time for  the Veteran to work with the counselor to resolve barrier s 
to service engagement, consider other treatment opti ons, and sustain motivation for and 
engagement in pain management and ancillary services . Moreover, meta -analyses and 
"dose -response" studies93,94 have suggested the benefit of several follow -up telephone 
sessions.  
 Coordination  with PACT Providers . The counselor  will communicate with the 
PACT nurse case manager  and primary care provider,  or other point -of-contact about 
recommended pain treatment referrals  primarily via the electronic health record . SBIRT -
PM counselors will write progress notes that indicate the SBIRT -PM encounter and 
outcome of each session, including asking the provider  to consider placing a consult for 
the Veteran’s preferred services or discussing the Vetera n’s interest in services at the 
Veterans next scheduled appointment. SBIRT -PM counselors cannot place consults for 
services directly; only PACT providers or other licensed p rofessionals working with the 
Veterans at their VAs can do so.  
 
SBIRT -PM Clinician Supervision .  
Dr. Martino will provide competency -based supervision to support the counselors ’ 
delivery of SBIRT -PM throughout the trial. This approach is consistent w ith the national 
VA Evidence -Based Practice training model,95 which emphasizes extended post -
workshop case -based supervision or consultation, including submission of audio 
recorded therapy sessions for treatment fidelity revi ew, as an essential training 
component. Dr. Martino will meet with the counselor s together on a 1 -hour monthly 
basis to review their SBIRT -PM practice. For these supervision meetings, he will l isten 
to and rate the counselors ’ SBIRT -PM fidelity for two sessions per counselor  (one initial 
and one follow -up call) using the Independent Tape Rater Scale 96 (see 3.C.3.8.10) for 
the purposes of feedback and coaching during supervisi on. In MI clinician training 
research, this approach and dose of supervision has been  shown to sustain proficient 
practice.97  
 
Adaptations to intervention in response  to COVID- 19. 
Study Product Guidelines and Considerations  30 of 67  Version 1.1 
  27 April 2020  Because the intervention is delivered via telephone a nd involves no in -person contact, 
we are able to continue to deliver the intervention during the coronavirus pandemic. 
However, several adaptations will occur.  
1. Access to in -person pain and substance use treatment is extremely  limited during 
the pandemic, while the VA has expanded telehealth/v ideo-based visits and 
treatments. Therefore, SBIRT -PM counselors will advise veterans on available 
telehealth /video services  and online resources for pain and substance use 
treatment  that Veterans are being referred to . 
2. Counselors will make themselves as widely available as  possible to 
accommodate tighter schedules.  
3. Empathy for the Veteran’s situation is a core feature  of Motivational Interviewing 
and many Veterans’ situations are dominated by COVI D-19. Therefore, empathy 
for COVID- 19 related issues that Veterans raise is being incorpor ated into the 
counseling.  
4. Because of the changing availability of treatment se rvices during the COVID -19 
period , the intervention will allow for one additional cou nseling session per 
veteran to occur between weeks 12 and 3 2. This session will be for the purpose 
of re-motivating veterans to engage in  available  pain and substance use services 
in view of any healthcare system changes that occurred.  The additional session 
maintains the integrity of our intervention in that t he counselor can fully influence 
veteran engagement in multimodal pain treatment and addiction services as 
those services’ availability changes.  
Counselors will determine on a case -by-case basis when to conduct this 
additional session based on when services become more available at each site 
and veteran preferences. Only one session will be per missible during this week 
12-32 period, regardless of the number of sessions compl eted during Weeks 1 -
12. All participants in the SBIRT -PM condition currently are within 32 weeks post -
randomization and thus eligible to receive the additi onal session. The additional 
counseling session will remain part of the protocol fo r the duration of the trial.  
 
Usual Care .  
A Veteran who completes a Compensation examination ordinarily has no further 
treatment, referral or debriefing as part of the Com pensation examination. Veterans 
assigned to the control condition will be contacted by the Project Director  and will be 
told they were assigned to the condition without additional study c ounseling. Veterans 
will be reminded that they should continue to pursue whatever counseling they need 
outside the study.  
Justification for No Additional Referral Control Con dition. No additional treatment 
is “treatment -as-usual” when a Veteran applies for service -connection. However, no 
treatment that a Veteran would otherwise get withou t participating in this study will be 
withheld. An active control group is important when an extens ive intervention is being 
tested and it is important to determine if the inter vention’s efficacy apart from non -
specific benefits from the time and effort expended b y the clinician. However, the need 
for an active control group is less compelling when c ompared  to a relatively brief 
intervention98 and when conducting a pragmatic trial where the emph asis is testing the 
effectiveness of innovations that improve upon usual  clinical care.99  
Study Product Guidelines and Considerations  31 of 67  Version 1.1 
  27 April 2020   
5.2 Handling of Study Interventions   
Study counseling sessions will be administered over th e telephone in accordance with  
the counseling manual. After a counseling session has occurre d, study counselors will 
place a note in the Veteran’s electronic medical reco rd indicating that a counseling 
session occurred and listing referrals the Veteran is int erested in having placed.  
5.3 Concomitant Interventions   
5.3.1  Allowed Interventions  
 N/A. Participation in this research study does not preclude use of any 
medications.  
5.3.2  Required Interventions  
 N/A.  
5.3.3  Prohibited Interventions  
 None  
5.4 SBIRT -PM Fidelity  Assessment  
SBIRT -PM fidelity assessment will involve tracking the numbe r of c ounseling sessions 
conducted per participant and the adherence and compet ence with which counselors  
conduct the sessions.  All SBIRT -PM sessions will be recorded and counselors  will 
maintain contact logs indicating all contact attempt s made to participants, result of each 
contact, and duration of each counseling session.  
 Adherence and Competence : We will randomly select 220 audio recorded 
SBIRT -PM sessions from the total number of sessions occurrin g in the trial (maximum = 
550 initial + 1650 follow -up sessions). Therefore, at a minimum we will have a  10% 
sample for validating that SBIRT -PM was delivered as intended. Specifically, the 
Independent Tape Rater Scale (ITRS ) will be used to assess the degree to which 
SBIRT -PM sessions were delivered with fidelity to MI (i.e.,  with adherence and 
competence). The ITRS includes items that cover thera peutic strategies that are MI 
consis tent (e.g. reflections) or inconsistent (e.g., unsol icited advice). For this trial, we 
added  three general items that detail the extent to which strateg ies for pain and 
substance use occurred in the sessions. For each item,  raters evaluate the counselors  
for adherence (i.e., the extent of intervention deli very) and competence (i.e., the 
skill/quality of intervention delivery) along 7 -point Likert scales. We will: 1) calculate 
mean adherence and competence scores for the two fac tors (fundamental and 
advance d MI strategies) identified in prior psychometric analy ses,96,100,101 and 2) 
determine if sessions achieve a criterion level for adequately performing MI, namely, at 
least half the MI consistent items rated average or above for both adherence and 
competence. In addition, we will evaluate the degree  to which clinicians addressed pain 
and substance use during the session, based on our g eneral items. We have 
documented experience training ITRS raters to perfor m reliable MI session process 
ratings in multi -site trials.102-106 
Study Product Guidelines and Considerations  32 of 67  Version 1.1 
  27 April 2020   For the data analyses, adherence to SBIRT -PM counseling will be dichotomized 
(“Having received counseling”  Yes/N o).  This approach is being taken because SBIRT -
PM’s duration and intensity is not hypothesized to rel ate to outcome; a Veteran might , in 
a single session , take steps to engage in non -pharmacological pain treatment that 
require minimal follow -up.  Conversely, a Veteran with more follow -up sessions might 
have more because the Veteran is more ambivalent abou t non -pharmacological pain 
treatments and is receiving more counseling because o f more need for it .  After the 
completion of the intent -to-treat analyses, the adherence indicator will be added to 
examine it as a potential mediator of response in the primary outcome analyses .  
6. STUDY PROCEDURES   
6.1 Schedule of Evaluations  
RCT Assessments  
  Assessment Name/Domain  Data Source  Baseline  12-wk 36-wk 
 
Socio -demographic Characteristics  Self-Report  x   
Psychiatric  and Substance Use 
Diagnoses  VA EHR - structured data 
(e.g. clinic codes)  x   
Characteristics  of Musculoskeletal 
Disorders  VA EHR, Service-
connection exam  x   
Distance to nearest  VA Facility VA EHR  x  
Brief Pain Inventory  Self-report  x x x 
Numeric  Rating  Scale  Self-report  x x x 
Opioid Medications Dispensed in 
Morphine Equivalent Daily Dose  VA EHR x x x 
Non-opioid Medications Dispensed  VA EHR x x x 
Non-pharmacological Pain 
Management Service Use —VA 
services  VA EHR - structured data 
(e.g. clinic codes)  x x x 
Non-pharmacological Pain 
Management Service Use ---VA and 
non-VA services VA EHR with Natural 
Language Processing  x x x 
Self-reported VA and non -VA service 
use Self-report  x x x 
ASSIST  Self-report  x x x 
Prescription Opioid Misuse  Self-report  x x x 
Nail clippings for drug/etoh use 
metabolites  Biological  x x x 
Substance Use Treatment Service 
Utilization – VA services VA EHR - workload data 
and clinic codes  x x x 
Self-reported VA and non -VA 
substance use service use  Self-report  x x x 
PHQ -9 (depression)  Self-report  x x x 
EQ-5D -5L Self-report  x x x 
PEG  Self-report  x x x 
Motivation  for engaging in pain 
treatment  Self-report  x x x 
Study Product Guidelines and Considerations  33 of 67  Version 1.1 
  27 April 2020  High Impact Pain Questions  Self-report  x   
Audit -C Self-report  x   
COVID -19 questionnaire  Self-report  x x x 
 
UG3 Preparation Assessments and End -of-Study Assessments  
Measures Described Earlier in 
UG3 Stage of RCT preparation  Data Source  UG3 
preparation 
phase End of 
Study 
Qualitative Interviews of 
Stakeholders  Self-report  x x 
Post-intervention Interview of 
SBIRT -PM-treated Veterans  Self-report  x  
Relational Coordination Survey of 
Key Stakeholders  Self-report  x x 
Treatment Fidelity Measure : 
Independent Tape Rater Scale  audio recorded SBIRT -PM session 
ratings   x 
 
6.2 Description of Evaluations   
6.2.1  Screening Evaluation  
A waiver of HIPAA authorization and waiver of informe d consent have  been  obtained to 
access lists of Veterans  applying for Compensation and Pension benefits for 
back/neck/knee/shoulder conditions at 8 study sites. Id entified i ndividuals who are  post 
9-11 status will be mailed a letter explaining the study. Individuals will be elig ible for 
enrollment for up to 6 weeks after the letter was ma iled.  The SBIRT -PM intervention 
acts by engaging Veterans in pain treatment, and Vet erans who have not engaged in 
three or more non -pharmacological pain treatment modalities (one of t he inclusion 
criterion) still are at the stage of care that they c ould benefit from the proposed 
counseling.   
Four days after the mailing, research assistants will f ollow -up the recruitment 
letters with a telephone call to fully screen Veteran s for inclusion in the study  using the 
participant screening form. Screening forms will be sav ed in the research study folder 
on the VA secure network.  The screening evaluation after the letters are mailed consist 
of a few questions about pain treatments received, pa in severity, and availability of a 
phone.   
Individuals who meet all inclusion/exclusion criteria and are in terested in 
participating in the study will be consented over the phone.  
Consenting Procedure  
A waiver of HIPAA authorization and a Waiver of Docume ntation of Informed Consent 
have been obtained to consent participants into the s tudy. Research Assistants will 
consent eligible individuals into the research study  by telephone call . Research 
Assistants will audio record the informed consent proce ss for individual to enroll him/her 
into the study. Audio files of the informed consent process will be saved in the research 
study folder on the VA secure network.  
 
Study Product Guidelines and Considerations  34 of 67  Version 1.1 
  27 April 2020  6.2.2  Enrollment, Baseline, and/or Randomization  
Enrollment  
The enrollment date is that day the individual has m et all the screening criteria and has 
agreed to participate in the study by completing audio -recorded informed consent.  
Baseline Assessments  
Measures to Characterize the Sample . 
• Socio -demographic Characteristics . A research assistant will collect self-reported  
socio- demographics (age, sex, race, ethnicity, marital status, education, employm ent 
status, legal status, and military history) from Veterans during  baseline assessment.  
• Medical Diagnoses. We will extract medical diagnoses from electronic health records 
and the VA Corporate Data Warehouse. We will identi fy psychiatric (e.g., 
depression, anxiety, Traumatic Brain Injuries,107,108  and PTSD109,110) and substance 
use disorders in the EHR and VA Corporate Data Wareho use by their ICD -9 and 10 
codes. We decided against more direct measures of ps ychiatric conditions (e.g. the 
PTSD Checklist) to minimize participant burden and react ivity.  To increase the 
sensitivity of our detection of psychiatric conditions, we will extract the service -
connection claims data from the Veterans Benefits Manag ement System for study 
participants at the end of their study participation.   New recipients of service -
connection receive it for an average of 5.25 distinct claims,40 and many Veterans file 
both MSD and claims for mental conditions at the same time. This will identify 
Veterans with psychiatric disorders who were diagnosed d uring their service -
connection examinations but do not have a diagnosis i n VA treatment records 
because they were not treated for their mental healt h condition.   
• Characteristics of Musculoskeletal Disorders. We will de termine the diagnostic group 
of MSD assigned to participants in the EHR by using IC D-9 or 10 codes. Major 
groups are back pain, neck pain, and osteoarthritis.  Other categories will be 
combined as suggested by their frequency and co -occurrence with other MSD. 
These include non -traumatic joint disorders, osteoporosis, sprain and str ain, 
traumatic joint disorder, spinal cord injury, fibromyal gia, rheumatoid arthritis, 
temporal mandibular disorder, lupus,  gout, and MSD multimorbidity (more than one 
MSD diagnosed). The broad MSD groups will be consid ered as potential moderators 
of treatment effect in the analyses. In addition, comp ensation examiners complete a 
detailed, structured form, the Disability Benefits Que stionnaire (DBQ), for each 
Veteran they evaluate. From these forms, we will ex tract structured notations of the 
examination findings.  Finally, we will obtain the f inal percentage service -connection 
awarded from the Veterans Benefits Administration System (VBMS) after the 
determination, and delineate service -connected conditions.  
 
Pain Measures : 
• Brief Pain Inventory (BPI). The Brief Pain Inventory111 (BPI) is a validated instrument 
to assess chronic non -cancer pain that yields two subscales.  One measures pain 
severity  (4 items on a 0 -10 scale) and the other assesses pain interference  with life 
activities (7 items on a 0 -10 scale), both using a 24 -hour recall period .  BPI  pain 
Study Product Guidelines and Considerations  35 of 67  Version 1.1 
  27 April 2020  severity  will serve as our primary pain outcome for the trial;  pain interference will 
serve as a secondary outcome. The BPI is a reliable measu re and responsive to 
change.112 The BPI is endorsed by the Initiative on Methods, Measu rement, and 
Pain Assessment in Clinical Trials (IMMPACT) group113 as a preferred measure of 
pain-related functioning . IMMPACT recommendations have specified score change s 
that would represent a minimally clinically important difference  (i.e., 30% reduction in 
pain severity and 1 -point reduction in pain interference), which will be  used in our 
cost analyses.114   
• Numeric Rating Scale (NRS) . The NRS115 is an 11 -point (0 = no pain, to 10 = worst 
pain imaginable) scale for current pain. It is the on ly pain measure collected at point -
of-care for every Veteran as part of the vital signs asses sment in Primary Care and 
entered into the EHR. The NRS has several shortcomin gs: a) Veterans may seek 
services when their pain levels are high, thereby maskin g longitudinal improvements 
in pain intensity; b) point -of-care contacts vary substantially among Veterans in 
Primary Care, rendering systematic analysis of changes in p ain symptoms difficult to 
ascertain in a clinical trial; and c) point -of-care NRS significantly underestimates pain 
intensity compared to same -day paper -and-pencil NRS assessments.116 Balancing 
the ubiquitous use of NRS with its limitations, we will  examine EHR -abstracted NRS 
ratings for participants as a secondary outcome.  
• PEG117. The PEG is a 3 -item scale assessing pain intensity (P), interference w ith 
enjoyment of life (E), and interference with genera l activity (G)  during the past week . 
It has good reliability, constructive validity, and se nsitivity to change and has been 
required by the  NIH-DoD-VA Pain Management Collaboratory Coordinating Center  
as a common measure across funded protocols.  
• High Impact Pain Questions . Three questions to determine the long -term impact  of 
pain are being asked:  “In the past 3 months, how often did you have pain?” ; “Over 
the past 3 months, how often did pain limit your life or work a ctivities”; “Are you not 
working or unable to work due to pain or a pain condi tion?  
 Answer choices consist of “never”, “some days”, “most da ys” or “every day”  for the 
first two questions and  yes/no  for the third question .  
  
Pain Treatment Services Received : 
• Opioid Medications Dispensed. We will extract dispens ed opioid medications and 
dosages from the patient’s electronic medical record and convert them to morphine 
equivalent daily dose using the procedures from a pub lished algorithm118 as adopted 
and operationalized by the PMC3 Phenotypes and Outcome s workgroup. 
Medications will be classified as opioids used to pain  as follows:  
(1) All non -IV fills of:  
   a) Codeine  
   b) Fentanyl  
   c) Hydrocodone  
   d) Hydromorphone  
   e) Morphine  
   f) Oxycodone  
   g) Oxymorphone  
   h) Tramadol  
Study Product Guidelines and Considerations  36 of 67  Version 1.1 
  27 April 2020  (2) All non -IV, pill/tablet pills of:  
   a) Methadone  
(3) All transdermal or buccal fills of  
   a) Buprenorphine  
MEDD is calculated by assuming prescriptions were taken  as directed. Total 
morphine equivalents are calculated by multiplying the quantity of each prescription 
by the strength of the prescription (milligram of op ioid per unit dispensed). Standard 
conversion factors on the CDC website will be used to  estimate the number of 
milligrams of morphine equivalents dispensed. Average da ily morphine equiva lent 
dose will be calculated by dividing total milligrams o f morphine equivalents by days 
supplied. For prescriptions that apn a particular mont h, only dates during that month 
will be included.  
The PMC3 Collaboratory recommends the following be c ollected,  and we will collect 
and analyze them per their recommendations:  
   a. Number of opioids supplied  
   b. Days supplied  
   c. a/b x conversion factor = milligrams morphine equiv alent daily dose (MEDD)  
   d. Mg MEDD at enrollment  
   e. Mg MEDD monthly during enrollment and at study com pletion.  
• Non-opioid Medications Dispensed. We will extract dispensed  non-opioid pain -
related medications from the medical record. These med ications will include topical 
analgesics, non -steroidal anti -inflammatory drugs, anticonvulsants, and 
antidepressants (specifically, selective serotonin and nor epinephrine reuptake 
inhibitors and tricyclic antidepressants). The presence or  absence of medications in 
each class will be the dependent measure.  
• Non-pharmacological Pain Management Service Utilization -VA Records . Dr. Goulet 
and the PRIME Center have an algorithm for identify ing visits from the EHR 
involving non -pharmacological management using workload information  entered at 
clinic visits (e.g. diagnosis treated, procedure perform ed) and the type of clinic 
provid ing the treatment.  
• Natural Language Processing -identified Non -Pharmacological Pain Management 
Service Utilization -VA and non -VA service use . This identifies dates at which the 
Veteran has reported “current use” of specific pain m anagement modalities.  
• Self-Reported Use of Pain Treatment Services . The PMC3’s phenotype and 
outcomes workgroup developed the “Use of nonpharmacological and self -care 
approaches” questionnaire to collect information abo ut patients’ use of 13 different 
pain treatments, including Acupuncture, Rehabilitation  Therapies, Manipulation, 
Massage, Yoga, Tai Chi/Qigong, Exercise, Biofeedback, Hy pnosis/ Hypnotherapy, 
Guided Imagery, Meditation, Psychotherapy/Counseling. In addition to asking about 
whether each treatment category was used, the instru ment also includes questions 
about the most important reason for use, whether th e treatment was received from a 
practitioner, the type of setting of use, how the se rvice was paid for, how often it was 
used, and how effective it was in relieving pain. Th e instrument was modified for this 
study  to collect information over the past 3 months (inste ad of past year), and to 
include several additional categories: Reiki, Pain S chool, Pain Clinic, primary care 
services, emergency/urgent care services, opiate and non -opiate medications.   
Study Product Guidelines and Considerations  37 of 67  Version 1.1 
  27 April 2020     
Substance Use Measures : 
• ASSIST . Substance use will be measured over the last 3 mo nths using Version 3.1 
of the Alcohol, Smoking and Substance Involvement Scre ening Test (ASSIST). After 
a screening question focusing on substances ever used, the ASSIST consists of 
seven questions about use of and consequences of use of each of ten classes of 
substances over the preceding three months (includin g nicotine). Scores are 
generated for each substance that are mapped to a t hree-point ordinal s cale of 
severity.119 As outlined in the World Health Organization’s Manual describing the use 
of the ASSIST to guide treatment recommendations, t he ASSIST ratings are scaled 
to represent no need for treatment, need for a brie f intervention, and need for an 
intensive intervention.  An advantage of the ASSIST is that these categories 
represent what clinicians consider a clinically import ant difference, in that they guide 
treatment recommendations. The items in the ASSIST h ave been shown to have 
good to excellent reliability for the substances assay ed. The reliability of the 
individual ASSIST items,120 and the ASSIST’s concurrent validity compared to oth er 
more detailed assessments of substance use severity121 have justified its adoption 
by the World Health Organization.122 We will obtain additional specifiers for 
substances requiring further characterization: a spec ifier about use of vaping for 
tobacco products, a specification as to whether the Ve teran is using legal or 
prescribed cannabis  and specification about use of prescribed amphetamine . 
• Prescription Opioid Misuse . Two questions,123 adapted from the CIDI124 for use in a 
NIDA Clinical Trials Network study,125 will be used to describe misuse of prescribed 
opioid medications: “How often have you taken your pain medications in l arger 
amounts than prescribed or for a longer period than p rescribed?” and “How often 
have you used your pain medicines to get high, to re lax, or to make you feel more 
alert?” The questions are asked about the preceding 4 weeks, with follow -up 
questions to clarify that the question refers to opio ids only.  
• Nail Collection and Measurement . Nail clippings will be assayed for metabolites of 
alcohol (ethyl glucuronide i.e. ETG), cannabinoids ( carboxy -THC, native -THC), 
opioids (6 -MAM, codeine, hydrocodone, hydromorphone, morphine,  oxymorphone, 
oxycodone), Amphetamines (amphetamine, MDA, MDEA, MDM A, 
methamphetamine), Cocaine (benzoylecgonine, cocaeth ylene, cocaine, norcoc aine) 
and Phencyclidine (PCP).  The tests are highly specific .  Samples are analyzed 
using an immunoassay technique (ELISA) and non -negative specimens are 
subjected to a gold standard confirmation technique ( GCMS or other method, 
depending on drug class). Nail, like hair, traps biomar kers in keratin but has higher 
concentrations of neutral and acidic biomarkers becaus e it has thicker keratin. In a 
study of hair and nails collected from the same peopl e, the rate of Carboxy -THC (an 
acidic biomarker for cannabis) positives for cannabinoid  at the SAMHSA -
recommended cutoff was 46.7% for hair and 53.3% for  fingernails and mean 
concentrations of the metabolite were five -fold higher in nails than in hair.126 In a 
study in the journal Addiction  of 606 college students,127 nail ETG at the 8 pg/mg 
threshold proposed for this study detected high -risk drinking with a sensitivity of 1.0 
and a specificity of .63. Receiver operating characteristic curves were signiﬁ cantly 
higher for ETG concentration in ﬁngernails than in hair fo r detecting risky drinking. 
Study Product Guidelines and Considerations  38 of 67  Version 1.1 
  27 April 2020  The biomarkers are incorporated throughout the nail p late from base to tip, by 
deposition of biomarkers from the capillary rich nail bed, thus allowing measurement 
by any nail clipping of sufficient weight. Biomarkers a re thought to reflect 3 -6 months 
of substance use history in fingernails, and toenails, which grow more slowly, reflect 
up to 9 months.  The detection window (3 -6 months) is close to the timeframe of the 
ASSIST (90 days), making cross -validation by the two measures reasonable.   
Approximately 100 mg of nail is required for analysis, w hich can be obtained 
from 2mm (a quarter’s width) of nail from each of te n digits. Samples will be mailed 
from home and thus un -observed, and participants will be provided with kits  for the 
nail clipp ing, and a financial incentive of $30 for providing each of the samples. We 
will also suggest Veterans set reminders to allow for  growth before clippings are 
needed.  
To reduce the risk that Veterans pass off someone else’ s fingernails as their 
own, they will be asked if the nails are theirs, and p aid regardless of whether they 
are. Specimen substitution when there are contingen cies for positive urines occurs, 
but there  is no incentive for such false reporting when paymen t is provided 
regardless of the sample results. The samples will be  mailed in coded envelopes 
addressed to our group, further reducing the likelih ood of submitting someone else’s 
fingernails.   
• Samples will be processed at the United States Drug Testing Laboratories (Illinois). 
After processing, samples will be destroyed following  a standard storage period. 
Sample analysis uses fully validated methods that have been inspected and 
approved by the College of American Pathologists Forens ic Drug Testing Program 
and the New York State Department of Health.  Substance Use Treatment Service 
Utilization -VA Records . Visits from the EHR involving substance use treatmen t will 
be identified conservatively, using an algorithm invol ving workload information 
entered at clinic visits (e.g. diagnosis treated, proce dure performed) and the type of 
clinic providing the treatment.  The measure does not  capture much substance 
abuse counseling in primary care settings, and in co njunction with other mental 
health treatment (i.e. , PTSD treatment).  For this reason, self -reported substance 
use service utilization will be collected (see below).  
• Self-Reported Use of Substance Use Treatment Services: Using the same format as 
the pain treatment service use questions described ab ove, we will inquire about 
whether  each of a number of classes of treatments was received  in the preceding 12 
weeks (substance use counseling, day program, residen tial, ER/hospital, self -help, 
counseling at a medical visit, counseling at a visit fo r a psychiatric condition, opioid 
substitu tion, smoking cessation counseling, nicotine replacem ent therapy 
prescribed).    
• Alcohol Use Disorders Identification Test (AUDIT -C)128.  This is an alcohol screen 
used to identify patients who are hazardous drinkers  or have active alcohol use 
disorders (including alcohol abuse or dependence). It  consists of three questions: 
“how often did you have a drink containing alcohol i n the past ye ar?”, “how many 
drinks did you have on a typical day when you were dri nking in the past year”, and 
“how often did you have six or more drinks on one occ asion in the past year”. It is 
scored on a scale of 0 (no use) through 12. In men, a score of 4 or more is 
considered positive and in women, a score of 3 or more  is considered positive.  
Study Product Guidelines and Considerations  39 of 67  Version 1.1 
  27 April 2020   
Other Measures : 
• Patient Health Questionnaire (PHQ -9). The PHQ -9 is a well validated screening 
measure for depression129 and will be used to identify probable depression as a 
covariate in analyses. It will also identify suicidal ide ation, which if severe, will trigger 
the need for further assessment (detailed in Human Su bjects).  
• EQ-5D-5L. The EQ -5D-5L is a standardized measure of health status designed t o 
provide a single index value of health for clinical a nd economic appraisals. It 
consists of five questions in the domains of mobility, self -care, usual activities, 
pain/discomfort, and anxiety/depression. .130 
• Motivation for engaging  in pain treatment131,132. Motivation for Change Scale to 
include 3 items (analogue scale coded from 1 to 100) t apping patient likelihood to 
engage in pain services, recognition of pain treatme nts as important, and pain 
treatment motivation.  
• COVID -19 questionnaire. These questions will assess participa nt infection status, 
adherence to COVID -19 safety regulations, and the effect that COVID -19 regulations 
have had on Veterans’ social determinants of health,  access to pain treatment, and 
access to substance use treatmen t. 
 
Qualitative Measures Collected in UG3 Phase and then  again at the end of the UH3 
Phase : 
• Relational Coordination Survey. This survey, will be a dministered post -trial to “hub” 
SBIRT -PM clinicians and “spoke” clinical and administrative st aff in Compensation 
and Pension and Primary Care to examine how pain car e was coordinated to meet 
the treatment needs of compensation -seeking Veterans.  It includes seven 
dimensions: frequency of communication, timeliness of c ommunication, accuracy of 
communication, problem -solving, shared goals, shared knowledge, mutual respec t). 
Respondents indicate the frequency in which each dimensi on exists in their setting 
on a 5 -point scale. The mean of the  individual scores serves as the overall RC score 
for each dimension within each spoke site.  
• Post-Trial Semi -Structured Qualitative Interview. At the end of the t rial, we will 
conduct in -depth interviews with “hub” SBIRT clinicians and “spok e” clinical and 
administrative staff in Compensation and Pension and Primary Care to assess the 
organization and coordination of pain management ser vices, given their experiences 
with SBIRT -PM implementation.  
 
Randomization  
The urn randomization covariates are: site (8 sites of VISN1), sex (M/F), race (White, 
Black, Other), ethnicity (Hispanic/Non- Hispanic ), and self -reported illicit drug use 
(Yes/No). Following enrollment and Baseline assessments, the Pr oject Director  will 
enter covariates into urn randomization program to determine intervention condition  
assignment . Randomization will occur within two weeks of the enro llment date.   
 
Study Product Guidelines and Considerations  40 of 67  Version 1.1 
  27 April 2020  6.2.3  Blinding  
Research assistants who collect study data will be blin d to participants’ treatment 
assignment. Veterans will be instructed during the assessments no t to tell the research 
assistant if they are receiving study counseling. To de termine if the blind was 
maintained, the research assistant will be asked to what condition each Veteran was 
assigned.  The PIs and Project Director will not be blind to ra ndomization, as they will be 
assigning study therapists to participants randomized to the treatment condition, 
reviewing counseling sessions for quality/fidelity, and c onducting monthly supervision 
with study counselors. The statistician has no contact w ith the study veterans; she will 
not be blinded.   
  
6.2.4 Follow -up Visits  
 
Research assistants will schedule telephone follow -up inte rviews approximately 12 
weeks (+ 4 weeks ) and 36 weeks (+ 4 weeks) after baseline visits. A 4 -week window for 
follow -up appointments allows for flexibility in scheduling an d provides sufficient time to 
complete assessments if an appointment is missed .  
 
Week 12 Follow -up 
See schedule of evaluations table and descriptions a bove.  
• Distance to nearest VA Facility. We will calculate the  driving distance from the 
Veterans’ address to the nearest VA medical facility providing integrated pain 
services care services.  Calculations will be done using google maps.  
 
Week 36 Follow -up 
See schedule of evaluations table and descriptions a bove.  
 
End-of-Study  
• Qualitative interview of stakeholders  
• Relational Coordinator survey of key stakeholders  
• Treatment fidelity: Independent T ape Rater Scale 
6.2.5 Completion/ Final Evaluation  
Participants’ final visit is the Week 36 follow -up. Participants will be contacted for week 
12 and 36 follow -up visits regardless of whether they engaged in study counseling. If 
the 12 -week  follow -up visit is missed and not completed within 4 weeks of t he 
appointment date, that follow -up will be missed and participant will be contacted fo r final 
week 36 follow -up visit.   
 Participation in study assessments and study counseling  is voluntary. 
Participants can participate in study assessments and ch oose not to engage in 
counseling. Reasons for terminating a participant prior to week 36 are: 
• Participant is found to not be eligible for the study after enrollment  
• Participant withdraws consent for further contact  
Study Product Guidelines and Considerations  41 of 67  Version 1.1 
  27 April 2020  7. SAFETY ASSESSMENTS  
The risk to Veterans who participate in this study is m inimal. Nevertheless, research 
staff will be trained in the detection and investiga tion of adverse events during the  
conduct  of study assessments or other interactions with participant s.   
Expected adverse experiences include : 
• Counseling session or study procedures upsets particip ant 
Criteria for management: Careful training of study staff and SBIRT -PM 
counselors will precede study initiation.  If a participant complains about study 
procedures  or counseling sessions , the complaint will be logged and will be 
brought to the attention of the mPIs.  Depending on the nature of the complaint, 
mPIs will decide whether the complain t requires follow -up directly with the 
participant.  
• Suicidal ideation detected by the PHQ -9 or by counseling  
Criteria for management: item 9  in the PHQ -9 identifies potential suicidal ideation  
(the questions asks about “thoughts of being better of f dead or of hurting yourself 
in some way” ). It is collected at baseline and at 12- and 36 -week follow -ups. Any 
positive response (response other than “none at all ”) to this question will be 
further evaluated, as well as other expressions of su icidality to the research 
assistant or SBIRT -PM clinician. Positive responses will be evaluated by one of 
the mPIs , Site -PIs, or covering providers. The response to clinical emergencies 
will be delineated in the Service Use Agreements betwe en the hub site and 
spoke for provision of SBIRT -PM. If the research team decides that the 
information must be reported, the person who spoke t o the Veteran (clinician or 
research assistant) will contact the Site-PI from the relevant medical center, and 
if he or she is not available, the clinician designat ed by the spoke site for 
handling mental health crises at the sites. All VISN 1 medical centers have 
emergency room facilities and a suicide prevention co ordination team. If the 
participant’s situation precludes management by spoke personnel (e.g. the 
Veteran is not accessible to VA staff or the site PI),  the Research Assistant will 
immediately consult with one of the mPIs about ways to  handle the situation, 
including calling for a  police safety check on the Veteran .  
7.1 Specification of Safety Parameters  
NA. 
7.2 Methods and Timing for Assessing, Recording, and An alyzing Safety 
Parameters  
Unanticipated problems will be recorded as they are discovered throughout the study. 
The Project Director  will record all reportable events with start dates o ccurring any time 
after informed consent is obtained until the last day  of study participation (approximately 
36 weeks after baseline).  At each study visit (Baseli ne, week 12, week 36), the study 
team will inquire about the occurrence of AE/SAEs sin ce the last visit.  
Our group completed a randomized controlled trial of 101 participants to a face -to-
face version of SBIRT -PM or two control conditions in a very similar popul ation to that 
Study Product Guidelines and Considerations  42 of 67  Version 1.1 
  27 April 2020  proposed in this application (Rosen et al., 2018).  T here were no study -related adverse 
events in that study, and they are unlikely in this stu dy as well.   
7.3 Adverse Events  and Serious Adverse Events  
An adverse event (AE) is any untoward medical occurr ence in a subject during 
participation in the research study. Veterans with MS D have a high frequency of 
medical and psychiatric difficulties. Therefore, changes  in medication regimen, the 
presence of medication side effects and symptom exace rbations are not untoward and 
do not constitute adverse events.  
Anticipated adverse events include complaints about the  study procedures and 
the counseling intervention, and any occurrence in wh ich the patient attributes 
discomfort, harm or disability to the study procedures.  
Serious adverse events (SAEs) are adverse events that res ult in: death, a life -
threatening experience, hospitalization, or the need  for medical, surgical, behavioral, 
social or other interventions to prevent such outcomes . Any report that a patient 
require d overnight treatment in any facility (emergency room,  detoxification, and 
hospitalization) will constitute a SAE. Hospitalizati on or death of another individual due 
to direct action of patient will also be considered a SAE.    
7.4 Reporting Procedures  
When an AE or SAE is reported by a participant, we wi ll ask for clarifying in formation 
describing the event.  Any SAEs will be immediately reported to Dr. Rosen a nd, if he is 
unavailable, to Dr. Martino. Reports to Dr. Rosen wil l include a description of the event 
and a summary of recent contacts with the patient. Th is summary will include any 
warning signs of the adverse event, the patient’s gen eral state and any information 
suggesting a causal link between study participation a nd the event.  
 SAEs that are unanticipated, serious, and possibly rel ated to the study 
intervention will be reported to the Independent Safety Monitor(s), IRB, and NCCIH  in 
accordance with requirements.   
• Unexpected fatal or life -threatening AEs related to the intervention will be 
reported to the NCCIH Program Officer, and Independent Safety Monitor (s) 
within 3 days of the investigator becoming aware of t he event.   
• Other unexpected SAEs that are related or probably study related will be 
reported to the IRB, NCCIH Program Officer, and Independent S afety Monitor(s) 
within 5 days. 
• SAEs and AEs that do not meet criteria for reporting w ithin five working days in 
accordance with VHA Handbook 1058.01 will be reporte d to the Central IRB  and 
the Independent Safety Monitor(s) ,at the time of continuing review (overall total 
and summary of types of events that occurred)  in accordance with their 
requirements.  Such events  will be reported to NCCIH on an annual basis.    
• All other AEs documented during the course of the trial wi ll be reported to NCCIH 
on an annual basis by way of inclusion in the annual  report and in the annual AE 
summary which will be provided  to NCCIH  and to the Independent Monitors.  The 
Independent Safety Monitor(s) Report will state that all AEs have been reviewed . 
Study Product Guidelines and Considerations  43 of 67  Version 1.1 
  27 April 2020   
7.5 Follow -up for Adverse Events  
The response to clinical emergencies will be delineat ed in the Service Use Agreements 
between the hub site and spoke for provision of SBI RT-PM. All VISN1 medical centers 
have emergency room facilities and a suicide preventi on coordination team. If the 
participant’s situation precludes management by spoke per sonnel (e.g. the Veteran is 
not accessible to VA staff or the site PI), the Resea rch Assistant will immediately 
consult with one of the mPIs about ways to handle the situation, including calling for a 
police safety check on the Veteran .  
 
7.6 Safety Monitoring   
A Data and Safety Monitoring Committee (DSMC) will b e appointed by NCCIH to review 
study progress, assess the adequacy of ongoing enrollmen t & site performance, ensure 
adequacy of data acquisition & protocol adherence and  evaluate overall safety 
throughout  trial implementation.  The DSMC will meet at least annually after trial 
initiation. A DSMC Charter Document outlining the o perating guidelines for the 
committee, the frequency of planned meetings and the specific data presentation format 
will be agreed upon during the initial meeting of t he DSMC. Study reports will be created 
by the study data center, following a standardized fo rmat, as directed by the DSMC. 
The DSMC will report directly to NCCIH.    
  
 Study progress and safety will be reviewed annually dur ing the RCT. Progress 
reports, including patient recruitment, retention/at trition, and AEs will be provided to the 
DSMB annually. This Annual Report will include a list and summary of AEs. In addition,  
the Annual Report will address (1) whether AE rates are consistent with pre -study 
assumptions; (2) reason for dropouts from the study; ( 3) whether all participants met 
entry criteria; (4) whether continuation of the stud y is justified on the basis that 
additional data are needed to accomplish the stated objectives  of the study; and (5) 
conditions whereby the study might be terminated pre maturely. The Annual Report will 
be sent to the Independent Monitor(s) and will be fo rwarded to the VA Central IRB and 
the NCCIH Program Officer within 1 month of each mon itoring rev iew.   
8. INTERVENTION DISCONTINUATION  
This study will be stopped prior to its completion if : (1) the intervention is associated 
with adverse effects that call into question the safe ty of the intervention; (2) difficulty in 
study recruitment or retention will significantly imp act the ability to  evaluate the study 
endpoints; (3) any new information becomes available d uring the trial that necessitates 
stopping the trial; or (4) other situations occur tha t might warrant stopping the trial.  
Study Product Guidelines and Considerations  44 of 67  Version 1.1 
  27 April 2020  9. STATISTICAL CONSIDERATIONS  
9.1 General Design Issues   
The pragmatic two-arm, parallel groups 36 -week randomized controlled single blind trial 
design was selected based on findings from a complet ed pilot study (Rosen et al., 
2018).  The study design parameters ---components of the intervention and its duration, 
duration of follow -up, and effect size estimates ---were largely derived from that study.  
Treatment -as-usual was selected as a control condition because t he question to be 
answered by this pragmatic trial is whether the interv ention is more effective than the 
status quo.  
 Our main objective is to test the effectiveness of SBI RT-PM, compared to Usual 
Care (UC), when delivered within a VISN1 -wide hub -and-spoke network.  
 Hypothesis 1 : SBIRT -PM will be more effective than UC in reducing pain severity 
as measured by the Brief Pain Inventory (primary outc ome #1).  
 Hypothesis 2 : SBIRT -PM will be more effective than UC in reducing the nu mber 
of substances categorized as requiring any interventi on (primary outcome #2) as 
identified by either self -report  (ASSIST)  or toxicolog ical analysis of nail clippings.   
9.2 Sample Size and Randomization  
 Given there are two primary outcomes (change in pain severity from the BPI, 
change in the number of substances whose use requires  intervention based on the 
ASSIST), Bonferroni correction was used to generate  a p-value of .025 for the sample 
size calculations for each outcome.  
 The planned (randomized) sample size is 1100 with sample selection at each site  
proportional to the size of the site. This sample siz e was based on power=.90 using 
alpha=.025, and an expected ES of d=.25 for pain  severity . Breakdown as follows: 400 
per group divided by ‘1 – loss to follow -up’ (73%) = 548 x 2 groups= 1096. Clustering 
was removed from the calculation  per the advice of the PMC3 Biostatistics workgroup 
leadership  during our protocol review. Instead , site will be controlled in analyses and a 
site by treatment interaction effect tested . In addition, power was increased to 90% 
based on their advice.  
 The planned sample size allows for 27% attrition. Val ues are based on previous 
related work and our 12 -week pilot study. In Poisson modeling of our pilot da ta, SBIRT 
was associated with a baseline -adjusted relative rate of pain -related appointments 
attended (a proposed mediator of SBIRT -PM) of RR (Exp(B))=1.6. 
 For substance use, the proportion converting to low  risk on at least one 
substance in the treatment group was estimated as 27%  and in UC as 10%. Attrition 
was set at 27%. For 90% power (alpha=.025), the cal culations resulted in sample size 
of 128 per group divided by ‘1 – loss to follow -up’ (73%) = 176 x 2 groups= 352 as the 
total sample size.  Given the sample size required fo r the pain outcome, a small effect 
size (absolute value of 6% between groups) would be d etectable for the substance use 
outcome with 90% power.   In the UG3 pilot study, 67% of the participants at baseline 
self-reported on the ASSIST a level of risky substance use ( either alcohol, tobacco or 
other drugs) that would require intervention  and 33% reported risky alcohol use .  
Projected to the full trial, this suggests 737 parti cipants are likely to have a clinically 
significant problem with at least one substance  and 357 will have a problem with 
Study Product Guidelines and Considerations  45 of 67  Version 1.1 
  27 April 2020  alcohol .  Thus, we will have an adequate sample in the UH3 RCT to d etect changes in 
our primary substance use outcome.  
 
 
Treatment Assignment Procedures  
The unit of randomization is participant. Participants w ill be randomized to SBIRT or 
Usual Care using a computerized urn randomization progr am within each site to 
increase the likelihood of balanced allocation of pa rticipants to the two interventions on 
several covariates: sex (male/female), race ( White , Black ), ethnicity (Hispanic /Non -
Hispanic ), and self -reported illicit drug use within 90 days (Yes/No) . All randomization 
will be done by the Project Director . 
Urn randomization preserves randomization as the prima ry basis for assignment 
to treatment and is less susceptible to experimenter b ias or manipulation of the 
allocation process by staff than is balancing. The ur n randomization algorithm allows 
probability of assignment to fluctuate as a function of the degree of covariate imbalance.  
As a study's sample size increases, urn and simple rand omization converge  because 
the treatment assignment probabilities under urn ran domization converge asymptotically 
to the  simple randomization probabilities.  
 
Blinding  
Research assistants who collect study data will be blin d to participants’ treatment 
assignment. Veterans will be instructed during the assessments no t to tell the research 
assistant if they are receiving study counseling. To de termine if the blind was 
maintained, the research assistant will be asked to wha t condition each Veteran was 
assigned.   
The PIs and Project Director will not be blind to ra ndomization, as they will be 
assigning study therapists to participants randomized to the treatment condition, 
reviewing counseling sessions for quality/fidelity, an d conducting monthly supervision 
with s tudy counselors. The statistician has no contact with th e study veterans; she will 
not be blinded.   
 
 
9.3  Definition of Populations  
  
 The study will occur within the eight VISN -1 VA medical centers (VAMC) located 
across six New England States. The medical centers are : Bedford VAMC; Boston 
Healthcare System; Central Western Massachusetts; Conne cticut Healthcare System; 
Maine Healthcare System, Manchester VAMC, Providence  VAMC, and White River 
Junction.  
 
Inclusion and exclusion criteria:  
 Inclusion criteria: 1) post -9/11 Veteran applying for MSD -related compensation  
(specified as back, neck, shoulder, or knee pain), as as certained from filed claim, 2) 
reports a score of  ≥4 (threshold for moderately severe pain)  on the BPI’s Pain Severity 
subscale (average of four pain intensity items); 3) avai lability of a landline or cellular 
telephone for SBIRT -PM.  
Study Product Guidelines and Considerations  46 of 67  Version 1.1 
  27 April 2020   Exclusion criteria : 1) reports inability to participate during the study  enrollment 
call; 2) received three or more non -pharmacological pain treatment modalities within the  
last 12 weeks from VA, and 3) participation in another PMC3 study as evidenced by a  
research protocol alert for that study at the time t he study invitation letter is mailed .   
 
 Participants who complete the baseline assessment and a re randomized to their 
treatment assignment will be the Intent to treat (IT T) population for analysis. The per -
protocol analyses will specify patients who participated the treatment and be conducted 
by including a variable indicating participation (Yes /No) in the ITT analyses. We will give 
precedence to the results of the ITT analysis over th e PP analysis.  
 
9.4 Interim Analyses  and Stopping Rules  
 
No interim analysis is planned.  An in -person version of the proposed intervention was 
tested in a completed study by this team (Rosen et al ., 2018).  There were no study -
related adverse events.   
 
There are no stopping rules.  
 
9.5 Outcomes  
 
9.5.1 Primary Outcome   
 
The two primary outcomes are pain severity as measured by the BPI  and the number of 
substances above the “no intervention” threshold in t he ASSIST.  We initially planned 
that when a positive toxicology result disagrees with a self -report of no use, the middle 
value on the ordinal scale (the indication to receive brief intervention) would be derived 
and used as the primary substance use outcome. However , only 64% of participants 
returned nail samples at baseline, and this percentag e dropped to 58% and 49% at 
week 12 and 36, respectively, among participants with c ompleted ASSIST 
assessments. Further, depending upon the substance and  timepoint, between 43% and 
48% of participants self -reporting a level of substance use that does not re quire an 
intervention, the group whose substance use classific ation would change with positive 
nail toxicology, did not have toxicology results. Given  the amount of missing toxicology 
data and that nails do not measure intervention need directly like the ASSIST, we plan 
to base our primary substance use outcome on the ASSI ST measure only. This change 
does not compromise our estimated power since the nu mber of participants self -
reporting a level of risky substance use that require s an intervention on the ASSIST 
(N=571) exceeds our assumed total sample size for thi s outcome (N=352) used in 
power analyses.  The BPI and ASSIST are collected at baseline, week 1 2 and week 36.  
 
9.5.2 Secondary Outcomes   
 
Secondary outcomes related to pain include non -pharmacological pain management 
service utilization, pain interference with life activities (BPI), overall pain (PEG), and 
overall health .   The non -pharmacological pain management service utilization wi ll be 
Study Product Guidelines and Considerations  47 of 67  Version 1.1 
  27 April 2020  summed across 13 possible modalities (injection; physic al therapy; chiropractic care; 
acupuncture; TENS; Spinal cord stimulator; cognitiv e behavioral therapy; 
mindfulness/acceptance and community therapy; treatmen t involving teaching about 
coping with pain; yoga, Tai chi or Reiki; massage tre atment; other treatment not already 
mentioned) as well as examined by individual modalities where s ufficient sample size is 
present.  
 Secondary outcomes related to substance use will incl ude severity measures for 
individual substances generated by the ASSIST, as w ell as toxicology results for 
individual substances.   
 
9.6 Data Analyses   
  
All variables (Intervention, covariates and outcomes) will be described with the use of 
the approximate summary statistics (mean, median, inter quartile range, and percent). 
Multivariate models will be used following the examina tion of bivariate tests of ou tcomes 
by intervention group. A successful outcome will be e ither a reduction in pain  severity  or 
number of substance use  above the “no intervention” threshold in the ASSIST or 
toxicologi cal analysis of nail clippings . The model type will be selected based on 
meeting of modeling assumptions including the outcome  distribution; Potential models 
will include linear and non -linear mixed -effects (Poisson (with over -dispersion), negative 
binomial, binary outcome) regression modeling.  If there is a large skew with many zeros 
(which is quite possible where the outcome is change in  the number of substances no 
longer needing intervention), we will use a negativ e binomial. If the distribution is a 
combination of 0’s (no change) and 1’s (change to level  of “no need for intervention” in 
one substance) with very few outcomes greater than 1 , a binomial distribution will likely 
be used.  A Poisson model will be used if there are v ery few successes and they have a 
Poisson distribution.  
These common rules will be used for guidance:  
• Poisson distribution, if mean = variance  
• Binomial distribution, if mean > variance  
• Negative binomial distribution, if mean < variance  
The covariance structure s will be explored to determine which (unstructured, com pound 
symmetry, autoregressive) is the most appropriate in mix ed models. Selection will be 
based on the lowest AIC. An intervention by time inte raction will be tested in the models 
– this will show the  effect of the intervention on the outcome compared to  controls.  
 Change in Pain: We anticipate using linear mixed -effects modeling to test the 
effect of SBIRT- PM on the 12 -week value of the BPI, if it is a normally distributed 
outcome. We will in addition test simultaneously the unique effects of treatment on pain 
outcomes at week 12 and week 36, controlling for bas eline differences, and test the 
equality of these parameters using the Wald test.   
Change in Substance Use: We anticipate using non -linear mixed -effects 
(Poisson, negative binomial, binary outcome  as discussed above) regression modeling 
to test the effect of SBIRT- PM on the number of substances requiring interventi on 
(according to the ASSIST), a count outcome.  One subs et of analyses will use risk sets 
Study Product Guidelines and Considerations  48 of 67  Version 1.1 
  27 April 2020  (at least 1 substance at baseline, at least 2 substa nces at baseline, etc.) to analyze 
substance risk changes in substance users. We will also test the equality of treatment 
effects at weeks 12 and 36 as described above.  
 We have identified stratification variables to accoun t for error variance as a 
recommended good practice. Key covariates to be inc luded in the model are 
depression, TBI, and mental health diagnoses (group ed into multiple more homogenous 
groupings, such as mood and psychotic disorders) as thes e are highly related to pain 
perception and substance abuse as well as the urn cov ariates – namely sex , race, 
ethnicity, self -reported illicit drug use and site. The strata used for the urn randomization 
are only to better ensure balance on key characteri stics. Their main effects will not be 
interpreted in the analysis, though they will be exam ined as potential modifiers of the 
intervention effect. We will also consider as potenti al covariates: distance to nearest VA 
medical center, number of pain treatment modalities used at baseline, reasons patient 
might drop out of the study, and the probability of withdrawal. Opioid -use will be 
examined as a mediator as well as a tertiary outcome.   Actual participation in SBIRT -
PM (Y /N) will be examined as a mediator of response.    
Per NIH policy, because there is considerable data sugges ting the importance of 
race, ethnicity  and sex  on the study outcomes (pain, substance use and service use), 
we will conduct an analysis that examines  sex and race/ethnicity as moderators  of 
treatment response. These analyses will be conducted  through the inclusion of 
interaction effects in models so sex and race/ethnicity effects can be formally tested.  In 
light of the differences in substance use, body hab itus, and substance metabolism 
between men and women, we will include a sex interaction term for the analysis of the 
relationship between self -reported levels of substance use and levels of ETG fo und in 
nail clippings.  While the use of subgroup analysis might be interestin g to look at sex -
specific characteristics such as the influence of pregn ancy or stage of menstrual cycle, 
we currently have no relevant covariates making the case for this type of sub -analysis . 
 
 
Sensitivity Analysis  
We anticipate some missingness will occur not completely at random. In general, m ore 
sensitive information such as use of illicit substan ces is less likely to be shared by 
participants  when responding to an interviewer .  Based on our previous study (R34), we 
anticipate there might be a difference in the follow -up rate between Veterans in the two 
arms of the trial, with veterans in the usual care a rm more frequently dropping out. We 
have created scenarios to minimize missing data through design  considerations (i.e., 
increasing our payment scale as incentive , regular reminder calls ), but our analytic plan 
includes the  investigat ion of  missingness . Patterns of missingness will be examined by 
each individual covariate in the data (univariate, mo notone or non -monotone). C hi-
squares and t -tests will be run to see if missingness is related to ot her variables in the 
analysis (for example : intervention status, substance use). We intend to  utilize multiple 
imputation in the case of variables missing either completely at random or at rando m. 
To reduce the likelihood of MNAR , the multiple imputation model will include “ auxiliary 
variables ” which are highly correlated with both the variable th at has missing data and 
the probability that the variable is missi ng. Sensitivity analyses will be conducted as part 
of the multiple imputation procedur e in SAS 9.4 (PROC MI) .  
 
Study Product Guidelines and Considerations  49 of 67  Version 1.1 
  27 April 2020  Sources of data  
Data for the study are drawn from patient self -report, VA electronic medical records of 
VA and community care, and the C&P examination. Veter ans requesting a 
Compensation & Pension evaluation for knee, shoulde r, neck or back pain may or not 
be receiving services from the VA. Persons who get all  their care outside of the VA will 
not have readily accessible medical records, while tho se persons who get some care in 
the VA but are sent out to community care for distinc t services (such as non -
pharmacological pain management) will have medical re cords of both types of care. In 
addition, those veterans who had not used any VA ser vices prior to their C&P request 
may then enter VA care following their C&P exam and will have EMR available only in 
the follow -up period.  The lack of EMR data of non -users of the VA will affect both the 
intervention or control arms of the study, and there is no reason to believe its effect will 
be differential.   
Acknowledging the variability in availability of EMR in formation, all subjects will 
have self -reported and C&P data regarding service use as well a s diagnoses. We will 
examine the concordance of self -reported and EMR -obtained information to estimate 
the impact of having no EMR data in the non -users of the VA. We will conduct a 
sensitivity analysis sub -setting the analyses only to those persons with availabl e EMR 
(as well as self -reported and C&P data).  
 
 
Cost-Effectiveness Analysis  
The relative cost -effectiveness of SBIRT -PM will be assessed using both incremental 
cost- effectiveness ratios (ICERs) and cost -effectiveness acceptability curves (CEACs). 
ICERs and CEACs will be calculated from the provider ( i.e., VISN and medical center) 
perspective. Using the cost estimates described in the Assessment subsection, we will 
calculate ICERs for minimal clinically important differe nces (MCID) between baseline 
and week -36 assessments in three primary outcomes: self -reported pain, risky alcohol 
use, and morphine -equivalent doses of opioid analgesic medication use.  
• Pain. Self -reported pain severity  and interference will be measured by the Brief Pain  
Inventory (BPI). A MCID in pain severity  will be a 30% reduction in ratings on this 
BPI subscale from baseline to week 36. The MCID for pain functioning will be a 1 -
point change in the BPI pain interference subscale.  We have followed the guidelines 
Erin Krebs followed in the SPACE trial for selectin g an MCID.  She states in her 
group’s 2018 JAMA report of the SPACE trial:   “Following consensus guidelines, this 
trial used a 1 -point difference as the MCID for BPI interference a nd BPI severity, and 
used a 30% reduction from baseline as MCID for mode rate improvement. ” 
• Substance Use . As noted earlier, the ASSIST categories represent what clinicians 
consider a clinically important difference, in that a difference the differences in risk 
category guide treatment. Therefore, we will conside r a net  decrease of one risk 
category (i.e. need for less overall treatment) acros s substances as the MCID.  
The ICERs will measure the incremental cost of usin g SBIRT -PM to produce a 
MCID in each of the outcomes. We will conclude SBIRT -PM’s cost -effectiveness for 
each outcome based on its ICER with respect to the t hreshold value placed by decision 
makers on the effect for that outcome. By using multiple outcomes, we can determine 
Study Product Guidelines and Considerations  50 of 67  Version 1.1 
  27 April 2020  the robustness of our cost -effectiveness findings and provide a more fine -grained cost -
effectiveness analysis to address different priorities  that stakeholders may have.186, 187  
To illustrate the uncertainty associated with ICER poi nt estimates, cost and effect 
estimates of SBIRT- PM will be bootstrapped (with 2,000 replicates) to pr oduce 
confidence intervals around the ICERs and to produce CE ACs for each outcome 
measure.188 CEACs quantify the uncertainty in the cost -effectiveness analysis by 
showing the probability that the intervention is cost -effective with respect to any given 
threshold value.188-190 Intuitively, as the threshold value of a MCID in a g iven outcome 
increases, the  strategy that produces that effect most efficiently bec omes increasingly 
more likely to be the most cost effective, even thoug h incremental costs are incurred. 
Similarly, as the threshold value of a MCID in a giv en outcome decreases, the strategy 
that has  the lowest cost becomes increasingly more likely to be  the most cost -effective. 
Finally, sensitivity analyses will be conducted to deter mine the robustness of the cost -
effectiveness results to alternative assumptions about  a wide variety of implementation  
parameters (e.g., cost of inputs).  
 
Budget Impact Analysis .  
 To demonstrate the financial feasibility of adopting SB IRT-PM, a budget impact 
analysis will be conducted. The per -person cost of SBIRT -PM will comprise the cost of 
delivering the intervention plus the cost of the VA -funded  services used by the 
participant in the SBIRT -PM condition over and above the cost of those used by 
individuals in UC, minus the yearly patient allocatio n (VERA dollars) assigned to that 
participant. The total projected yearly cost to a gi ven medical cent er of SBIRT -PM will 
be the per -perso n cost times the total number of Veterans applying for compensation 
and pension for a musculoskeletal condition times the  expected rate of uptake.  
 
Analyses of NLP Algorithms  
 We will identify the use of non -pharmacological pain modalities through self -
report from the participants as well as two different  approaches to the extraction of 
healthcare utilization data from electronic medical re cords.  Medical record extraction of 
1.)  Structured data - stop codes indicating use of these modalities, and 2 .) Unstructured 
data - domains identified in the application of the NLP me thod to the medical record 
data of study participants. Two independent researcher s will identify words/snippets that 
suggest use of specific non -pharma modalities and rate enough snippets to have 
software reliably generate an algorithm to rate all p atients included in the study on each 
modality (machine learning). As we expect false posit ive reports of use of a modality to 
be unlikely, identification of use during an assessment  period by any of the three 
methods (self -report, medical record stop codes and NLP) will be c onsidered use.   The 
agreement between these different measures will be d escribed by cross -tabs. 
 
10. DATA COLLECTION AND QUALITY ASSURANCE  
10.1 Data Collection Forms   
Research Assistants will screen and collect contact info rmation for all study subjects on 
the “Participant Screening and Contacts Form”. Inform ation will be collected by 
Study Product Guidelines and Considerations  51 of 67  Version 1.1 
  27 April 2020  Research Assistants over the telephone and entered dire ctly into the electronic form. 
Forms are saved in a restricted research folder on secu re VA networked computers.  
Research Assistants will collect all baseline and follo w-up interview data  by 
telephone interview with the participants. They will e nter data directly into REDCap 
questionnaires. Research assistants are blind to parti cipant’s randomization group. 
REDCap questionnaires and data are saved in VA REDC ap and in a restricted research 
folder on secure VA networked computers. VA REDCap ca n only be accessed on the 
secure VA Network.  
Electronic medical record data will be accessed and sto red on the VA Informatics 
and Computing Infrastructure (VINCI) platform and i n a restricted research folder on 
secure VA networked computers.  
 
10.2 Data Management   
 
VA REDCap is a secure web application for building an d managing online 
surveys that can be used for direct data entry by Rese arch Staff. Project questionnaires 
will be created and used for data collection. After data are collected, REDCap provides 
automate d export procedures for data to be downloaded to Ex cel and common 
statistical packages (SPSS, SAS, R) for data analysis. In  these programs, filters flag 
data that needs to be re -checked by a person such as unclear characters, out -of-range 
variables and logical inconsistencies. The project dir ector and project statistician will 
check files monthly so that errors can be readily correct ed and consequential 
differences between treatment types (e.g., differen t levels of attrition) can be monitored 
closely.  
10.3 Quality Assurance  
10.3.1  Training  
Training of Study Counselors   
Dr. Martino will provide competency -based supervision to support the counselors ’ 
delivery of SBIRT -PM throughout the trial. This approach is consistent w ith the national 
VA Evidence -Based Practice training model,95 which emphasizes extended post -
workshop case -based supervision or consultation, including submission of audio 
recorded therapy sessions for treatment fidelity revi ew, as an essential training 
component. Dr. Martino will meet with the counselors  together on a 1 -hour monthly 
basis to review their SBIRT -PM practice. For these supervision meetings, he will l isten 
to and rate the clinicians’ SBIRT -PM fidelity for two sessions per counselor  (one initial 
and one follow -up call) using the Independent Tape Rater Sc ale 96 for the purposes of 
feedback and coaching during supervision. In MI clinicia n training research, this 
approach and dose of supervision has been shown to sus tain proficient practice.97  
The risk of angering or alienating Veterans is low be cause of the non -
confrontational nature of SBIRT -PM. The risk will be further minimized by hiring 
experienced counselors  who have experience with the study population. Study 
counselors  will be trained to adopt a collaborative approach. S tudy counselors  will also 
be knowledgeable about the location of emergency roo ms, VA Police, and crisis 
Study Product Guidelines and Considerations  52 of 67  Version 1.1 
  27 April 2020  services available at each VISN1 medical center, as wel l as mandated reporting 
procedures for all sites .  
 
Training of Study Research Assistant   
Staff obtaining verbal consent will have completed a web -based course with post -test 
on Human Research Protections, and all will have had  specific training by the mPIs in 
obtaining informed consent for this project.  
The research assistant will receive training in the st udy assessments from the 
Project Director and the two mPIs.  The research assis tants will administer the study 
consent and assessments to other staff in role plays un til they are administered 
correctly.   Research assistants will be asked to contact the PIs about  participant 
responses that are not obvious to code within the o ffered choice options.   
The research assistant will also be knowledgeable about  the emergency facilities 
(emergency rooms, VA Police, and crisis services) at each VISN1 medical center. The 
research assistant will also receive training in de -escalating agitated Veterans.  
COVID -19 response: the research assistants collecting self -report data about 
pain and substance use service utilization will prompt  veterans to consider in -person 
and all telehealth/virtual and telephone -delivered services when responding to our 
service utilization assessment.  
 
10.3.2  Quality Control Committee  
NA 
10.3.3  Metrics  
Study progress and safety will be reviewed monthly by the mPIs and Project Director. 
An Annual Report will be sent to the Independent Mo nitor(s) and will be forwarded to 
the VA Central IRB and the NCCIH Program Officer wit hin 1 month of each monitoring 
review. 
Data type  Frequency of review  Reviewer  
Subject accrual (including compliance 
with protocol enrollment criteria)  Monthly  PI, Project Director 
Annually  DSMB  
Status of all enrolled subjects, as of 
date of reporting  Monthly  PI, Project Director 
Annually  DSMB  
Data entry quality control checks on 
10% of charts  
 
These checks will consist of verifying 
that there is no missing data ( except 
for patient refusals for specific items) 
and all assessments are completed. 
In REDCap, if a question is not 
answered, a box will pop up 
highlighting the unanswered 
questions before it allows the RA to 
“complete” the form. This will allow 
veterans to answer an y missing items Monthly  Project Director  
Study Product Guidelines and Considerations  53 of 67  Version 1.1 
  27 April 2020   
10.3.4  Protocol  Deviations  
Protocol deviations will be reported to mPIs  as they are discovered.  mPIs will report 
protocol deviations to the VA Central IRB according t o cIRB policies.  
10.3.5  Monitoring  
The Project Director will create study checklists for  each data collection point to ensure 
data is collected as outlined in the approved protoc ol. All self -reported survey data will 
be collected directly in VA REDCap. VA REDCap is a sec ure web application for 
building and managing online surveys that can be used  for direct data entry by 
Research Staff. Project questionnaires can be creat ed and used for data collection. 
After data are collected, REDCap provides automated  export procedures for data to be 
down loaded to Excel and common statistical packages (SPSS, SAS , R) for data 
analysis. In these programs, filters flag data that ne eds to be re -checked by a person 
such as unclear characters, out -of-range variables and logical inconsistencies. The 
Project Direc tor will check files monthly so that errors can be read ily corrected and 
consequential differences between treatment types (e. g., different levels of attrition) can 
be monitored closely. Data quality will be monitored by random inspection of the 
completed forms monthly by the Project Director and any problems detected wi ll be 
discussed with the mPIs. Recruitment and retention dat a will be reviewed and reported 
to study leadership monthly.  
 
We will collect data about SBIRT -PM implementation. Specifically, we will report 
the percentage of participants who received different “doses” of the intervention (i.,e., 0, 
1, 2, 3, or 4 sessions).  We also will track the percen tage of each counselor’s ass igned 
Veterans who receive counseling and the percentage wh ose first counseling session is during the same telephone call.  If a 
question is refused by the veteran it 
will be left blank and the RA will put a 
note in saying it was refused.      
Adherence data regarding study visits 
and intervention  Monthly  PI, Project Director 
Annually  DSMB  
AEs and rates  Monthly  PI, Project Director 
Annually  DSMB  
Annually  NCCIH, VA Central IRB 
SAEs (unexpected and related)  Per occurrence  PI, DSMB, 
NIH/NCCIH  
SAEs (expected or unrelated)  Per Occurrence  PI, Project Director 
Annually  DSMB, NIH/NCCIH  
Unanticipated Problems  Per Occurrence  PI, Project Director 
Per Policy VA Central IRB 
Study Product Guidelines and Considerations  54 of 67  Version 1.1 
  27 April 2020  followed by a second. In our pilot, 80% of participa nts received the assigned counseling, 
and 55% of those who received any counseling had at least two sessions. If a counselor 
falls below 70% of participants receiving any counselin g within 12 weeks or below 50% 
of a second session among those with a first, we wil l take the following steps: 1) 
compare that counselor’s procedures to “best practices ” by other counselors.  Such best 
practices might include time of day Veterans are cal led, and the negotiation a round 
scheduling the calls; and 2) contact the site PI to de termine if sub -optimal engagement 
is a site -specific issue.  Two examples of site -specific issues are cell phone reception 
and local VA hospital reputations.  In very rural ar eas, poor cell phone coverage makes 
participation more difficult, and it may be more diff icult to engage Veterans when the VA 
facilities in their local communities have a damage d reputation.   
Clinicians will receive standardized training for SBIR T-PM, with their fidelity 
monitored by Dr. Martino using a competency -based supervision approach. We will 
independently rate a random sample of about 10% of t he SBIRT -PM sessions (n = 220) 
for the counselors’ adherence and competence in deli vering the intervention using the 
Independent Tape Rater Scale.  The ITRS has two fact ors - fundamental and advan ced 
motivational interviewing strategies, as well as a cl inical consensus -based benchmark 
of adequate proficiency, namely, half of the 10 motivat ional interviewing consistent 
items being rated > 4 for both adherence and competence.  We will repor t the mean 
factor scores for adherence and competence, as well as the percentage of sessions that 
meet adequate proficiency standards in the random sam ple as a reflection of our 
success in implementing SB IT-PM during the trial.  To support high -integrity 
implementation during the trial, Dr. Martino will r eview two sessions per counselor per 
month using the ITRS and provide feedback and coaching  to the counselors in monthly 
supervision meetings.  Should a counselor fall below an adequate level of performance 
on two consecutive sessions reviewed by Dr. Martino, he will review one session per 
week from that counselor and meet with the counselo r individually for more intensive 
supervision until the counselor’s proficiency reaches a dequate or better standards once 
again.  
 
11. PARTICIPANT  RIGHTS AND CONFIDENTIALITY   
Subject confidentiality is strictly held in trust by t he investigators, study staff, and the 
sponsor(s) and their agents.  This confidentiality is extended to cover test ing of 
biological samples in addition to study information  relating to subjects.   
The study protocol, documentation, data, and all oth er information generated will 
be held in strict confidence.  No information concer ning the study or the data will be 
released to any unauthorized third party without pri or written approval of the sponsor.  
The study monitor or other authorized representatives of the sponsor may 
inspect all study documents and records required to b e maintained by the investigator, 
including but not limited to, medical records (offic e, clinic, or hospital) for the study 
subjec ts. The clinical study site will permit access to such r ecords.  
11.1 Institutional Review Board (IRB) Review   
The VA Central IRB has approved the study applicatio n (containing a VA Central IRB 
Study Product Guidelines and Considerations  55 of 67  Version 1.1 
  27 April 2020  protocol, waivers, application forms, etc .). Any subsequent modifications will be 
reviewed and approved by the VA Central IRB and inc orporated into this NCCIH 
protocol.  
11.2 Informed Consent Forms  
Veteran Participants  
Voluntary informed consent will be obtained from all  Veterans prior to 
participation. Research assistants will conduct the informed consent process with 
participants over the telephone. The Informed consen t process and the participant’s 
agreement to participate will be documented in an au dio file.  
Veterans will be provided with information about th e SBIRT -PM intervention, how 
long it will last, the nature of study assessments, inf ormation about the collection of 
biological specimens, the examination of their elec tronic health care and VA data, and 
potential risks and benefits of study participation. Vet erans will be reminded that they 
can withdraw from the study at any time without penalt y. They will be given the 
opportunity to ask questions and then will be asked if  they agree to participate.  
Veterans who agree to participant will state so for the audio -recording. Audio -
recorded consents will be stored on VA Network comput ers behind the VHA firewall.  
 
VA Staff Participants  
 Voluntary informed consent will be obtained from all  VA staff interviewed for the 
study prior to participation. For the qualitative int erviews,  Research staff will describe 
the purpose of the interview prior to administering t hese assessments. Participating VA 
staff members will be encouraged to ask any questions a nd have the option to 
discontinue participation without prejudice. They will be approached by people other 
than their direct supervisors.  After a brief reiteration of the study purpose, the  
interviewer will confirm consent to record the interview f or transcription and analysis 
purposes before proceeding.   A waiver of documentation of informed consent for VA  
staff participants has been obtained.  No documentation will be obtained.   
 For the survey, a survey invitation will be emailed to VA staff directly from 
REDCap. The invitation will explain the purpose of the survey and who will have access 
to the results.  
11.3 Participant Confidentiality   
Privacy and Confidentiality of Veteran Participant Data: 
Data Storage - All possible precautions will be taken to prevent a  breach of 
confidentiality.  
1. Minimizing PHI in study databases: Research data will  be identified by code 
number and will not include names, although enrollm ent records must also be 
kept and these records will include names. Our study  forms have been designed 
to avoid collecting identifiable information; no Pr otected Health Information (PHI) 
will be collected on study forms. We collect only pro tocol session dates. These 
dates are changed to ‘number of sessions completed’ w hen data sets are 
anonymized and released to other investigators.   
2. Data with PHI: Personal identifiers will be retained to obtain VA service use data 
from central VA databases. The personal identifiers w ill be used to identify 
Study Product Guidelines and Considerations  56 of 67  Version 1.1 
  27 April 2020  service use by study participants from the VA central da ta repositories. Study 
data will be stored and analyzed on VA secure network  computers and in the VA 
Informatics and Computing Infrastructure (VINCI). VIN CI is a Department of 
Veterans Affairs (VA) He alth Services Research & Development (HSR&D) 
resource center that provides a secure, central anal ytic platform for performing 
research and supporting clinical operations activities . It is a partnership between 
the VA Office of Information Technology (OI&T)  and the Veterans Health 
Administration Office of Research and Development (VHA  ORD). VINCI includes 
a cluster of servers for securely hosting suites of dat abases integrated from 
select national VA data sources. VINCI servers for data , applications and vir tual 
sessions are physically located at the VA Austin Informa tion Technology Center 
(AITC), located in Austin, Texas. This secure enclav e with 105 high -performance 
servers and 1.5 petabytes of high -speed data storage has multiple layers of 
security and disaster recovery to prevent data loss. T o ensure the protection of 
Veteran data, VINCI maintains compliance with the g uidelines set forth by 
Veterans Health Administration (VHA) Handbook 1200.1 2, Use of Data and Data 
Repositories in VHA Research, and all other applicable  VA and VHA policies and 
regulations. In addition, VINCI has undergone all s ecurity certification activities in 
support of obtaining an Authorization to Operate (ATO ). Access to VINCI 
resources are approved in accordance with the require ments of National Data 
Systems (NDS), VHA Handbook 1200.12, Use of Data and Da ta Repositories in 
VHA Research, and all other applicable VA and VHA pol icies and regulations. All 
data transferred from VINCI is subject to audit for compliance. VA -credentialed 
resea rch staffs are granted access to study -specific data along with tools for 
analysis and reporting in the secure, virtual working  environment through a 
certified VHA network computer within the VA.  If not  working within a VA or VHA 
hosted office environment  containing VA network access, researchers may apply 
for and then access VINCI through an approved Virtual  Private Network (VPN) 
and Remote Desktop application. The remote computing  environment enables 
data analysis to be performed directly on VINCI server s, offering several  
advantages: uniform security standards for access; a com mon point of entry for 
all investigators who use the data; tools for analysi s and reporting; tighter and 
more consistent control of data quality; and the abil ity to standardize and  update 
terminology and format as technology and methodology  improve. After the 
needed service use information is extracted, the ident ifiers will be removed to 
create files with de -identified data for subsequent analyses. At the conc lusion of 
the study, al l files with identifiers will be destroyed. The files wi th identifiers will 
be stored on VA secure network computers. Data Securi ty will be insured by 
using servers which all reside completely behind the V A firewall. There is no 
public internet access. Another layer of protection fo r sensitive information is 
ascribed to the system by use of granular access privileg es. Only authorized staff 
will have data access. Study managers have the capabil ity of granting access 
and read -write privileges to users. All sy stems undergo daily backup and 24 -hour 
security. 
3. Clinical enrollment records are kept separate from r esearch data. Participants’ 
names will appear only on the consent form, HIPAA au thorization form, and “key” 
Study Product Guidelines and Considerations  57 of 67  Version 1.1 
  27 April 2020  form kept by the mPIs. All paper forms will be stored  and secured in a locked file 
cabinet under the jurisdiction of the Dr. Rosen.  
4. Presentation of Study Results: The research records w ill be used to prepare 
reports that do not allow for the identification of individual study participants.  
5. Communication by Research Staff: All computers used b y research staff are 
password protected. All research staff and counselors r eceive annual Good 
Clinical Practice, Human Subjects Protection, HIPAA, a nd VHA privacy training 
through Yale and the VA. Our data collection and ma nagement procedures are 
fully compliant with HIPAA.  
 
Confidentiality of Digital Audio Recorded Counseling  Sessions - To assure the 
confidentiality and protection of participants with res pect to digital audio recording of 
SBIRT -PM sessions, the following steps will be taken:  
1. Participants will provide informed consent for digita l audio recording. Participants 
will be allowed to participate in the study and refu se the audio recording. 
Participants who do consent to audio recording will b e informed that they have 
the right to stop the audio recording at any time du ring the session.  
2. Digital audio recordings will be treated as confide ntial research records. They will 
be labeled with a unique study ID code and uploaded  to a secure network VA 
server, separate from other study data. The audio fil e name will use study ID 
codes.  
3. Access to audio recordings will be limited to members o f the investigative team 
including trained research raters who will rate the recordings according to the 
clinician adherence and competence rating system and on ly the research staff 
will have access to  the recordings. A separate file will link the audio recording file 
code to the participant’s unique identification code, the clinician’s name, and the 
date of the session.  
 
Privacy and Confidentiality of VA Staff Participant Data: 
VA staff will have the right to stop the audio reco rding at any time during the interviews. 
These recordings will be treated as confidential res earch records, labeled with unique 
study ID codes, and uploaded to a secure network VA s erver. Recorded interviews will 
be transcribed by VA staff in the Centralized Transcrip tion Service Program (CTSP) in 
Salt Lake City, UT. THE CTSP ensur es VA privacy and security requirements are met 
by operating within the VA firewall. Both audio rec ordings and transcriptions will be kept 
behind the VHA firewall. Access to survey data and reco rdings will be limited to 
members of the investigative team in  involved in managing, analyzing, and interpreting 
them.  
11.4 Study Discontinuation  
The study may be discontinued  at any time by the IRB, the NCCIH , the OHRP, the FDA, 
or other government agencies as part of their duties  to ensure that research participants 
are protected.  
Study Product Guidelines and Considerations  58 of 67  Version 1.1 
  27 April 2020  12. COMMITTEES  
NCCIH P rotocol Review Committee (PRC) is an external committ ee appointed by 
NCCIH to review clinical study documents and provide  specific recommendations to 
NIH. 
 
Pain Management Collaboratory Coordinating Center (P MC3) Steering Committee 
provides administrative support, project management, quality management and 
communications between study projects. The committee will address issues that span 
all projects and provide input into the policies and p rocesses of the N IH-DoD-VA PMC. 
This includes guiding the demonstration projects and work groups to develop best 
practices and tools to foster harmonization. Steering Committee Members include Bob 
Kerns (Chair), Cindy Brant, Peter Peduzzi (Co -PIs), PIs from each demonstrat ion 
project, work group representatives, NIH, DoD, VA Pro gram Coordinators, Program 
Officers/Project Scientists, and subject matter experts . 
13. PUBLICATION OF RESEARCH FINDINGS  
Publication of results from this study’s data will be overseen by Drs. Rosen and 
Martino.  Publications that result from data compil ed across PMC3 studies will be 
subject to the PMC3 Collaboration Publication policy.   
14. REFERENCES  
1. Hing E, Cherry DK, Woodwell DA. National Ambulatory  Medical Care 
Survey: 2004 Summary. In: U.S. Department of Health  and Human Services, ed.: 
Centers for Disease Control and Prevention, Nationa l Center for Health Statistics; 
2006.  
2. Gironda RJ, Clark ME, Massengale JP, Walker RL. Pai n among veterans of 
Operations Enduring Freedom and Iraqi Freedom.[see comment]. Pain Medicine 
2006;7:339 -43. 
3. Haskell SG, Brandt CA, Krebs EE, Skanderson M, Kern s RD, Goulet JL. 
Pain among Veterans of Operations Enduring Freedom and Iraqi Freedom: do 
women and men differ? Pain Medicine 2009;10:1167 -73. 
4. Haskell SG, Ning Y, Krebs E, et al. Prevalence of p ainful musculoskeletal 
conditions in female and male veterans in 7 years a fter return from deployment in 
Operation Enduring Freedom/Operation Iraqi Freedom.  The Clinical Journal of 
Pain 2012;28:163 -7. 
5. Knauer SR, Freburger JK, Carey TS. Chronic Low Back  Pain Among Older 
Adults: A Population -Based Perspective. Journal of Aging and Health 
2010;22:1213 -34. 
6. Macey TA, Morasco BJ, Duckart JP, Dobscha SK. Patte rns and correlates 
of prescription opioid use in OEF/OIF veterans with  chronic noncancer pain. Pain 
Medicine 2011;12:1502 -9. 
7. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guid elines for the use of 
chronic opioid therapy in chronic noncancer pain. J ournal of Pain 2009;10:113 -30. 
Study Product Guidelines and Considerations  59 of 67  Version 1.1 
  27 April 2020  8. Committee on Advancing Pain Research Care IoM. Reli eving pain in 
America: A blueprint for transforming prevention, c are, education, and research: 
National Academies Press; 2011. Report No.: 0309214 84X. 
9. Committee on Advancing Pain Research Care, Institut e of Medicine. 
Relieving pain in America: A blueprint for transfor ming prevention, care, 
education, and research: National Academies Press; 2011. Report No.: 
030921484X.  
10. Hill JC, Whitehurst DG, Lewis M, et al. Comparison of stratified primary 
care management for low back pain with current best  practice (STarT Back): a 
randomised controlled trial. The Lancet 2011;378:15 60-71. 
11. Ferreira ML, Ferreira PH, Latimer J, et al. Compari son of general exercise, 
motor control exercise and spinal manipulative ther apy for chronic low back pain: 
a randomized trial. Pain 2007;131:31 -7. 
12. Cherkin DC, Deyo RA, Battié M, Street J, Barlow W. A comparison of 
physical therapy, chiropractic manipulation, and pr ovision of an educational 
booklet for the treatment of patients with low back  pain. New England Journal of 
Medicine 1998;339:1021 -9. 
13. Lamb SE, Hansen Z, Lall R, et al. Group cognitive b ehavioural treatment for 
low-back pain in primary care: a randomised controlled trial and cost -
effectiveness analysis. The Lancet 2010;375:916 -23. 
14. Wetherell JL, Afari N, Rutledge T, et al. A randomi zed, controlled trial of 
acceptance and commitment therapy and cognitive -behavioral therapy for 
chronic pain. Pain 2011;152:2098 -107. 
15. Tilbrook HE, Cox H, Hewitt CE, et al. Yoga for Chro nic Low Back PainA 
Randomized Trial. Annals of Internal Medicine 2011; 155:569 -78. 
16. Sherman KJ, Cherkin DC, Wellman RD, et al. A random ized trial comparing 
yoga, stretching, and a self -care book for chronic low back pain. Archives of 
Internal Medicine 2011:archinternmed. 2011.524 v1.  
17. Schmidt S, Grossman P, Schwarzer B, Jena S, Naumann J, Walach H. 
Treating fibromyalgia with mindfulness -based stress reduction: results from a 3 -
armed randomized controlled trial. Pain 2011;152:361 -9. 
18. Morone NE, Greco CM, Weiner DK. Mindfulness meditat ion for the 
treatment of chronic low back pain in older adults:  A randomized controlled pilot 
study. Pain 2008;134:310 -9. 
19. Plews ‐Ogan M, Owens JE, Goodman M, Wolfe P, Schorling J. BRIEF 
REPORT: A Pilot Study Evaluating Mindfulness ‐Based Stress Reduction and 
Massage for the Management of Chronic Pain. Journal  of General Internal 
Medicine 2005;20:1136 -8. 
20. The Management for Opioid Therapy for Chronic Pain Working Group. 
VA/DoD Clinical Practice Guideline for Management o f Opioid Therapy for 
Chronic Pain. 2.0 ed: Office of Quality and Perform ance; 2010.  
21. Lin LA, Bohnert AS, Kerns RD, Clay MA, Ganoczy D, I lgen MA. Impact of 
the Opioid Safety Initiative on opioid -related prescribing in veterans. PAIN 2017.  
22. Morasco BJ, Gritzner S, Lewis L, Oldham R, Turk DC, Dobscha SK. 
Systematic review of prevalence, correlates, and tr eatment outcomes for chronic 
Study Product Guidelines and Considerations  60 of 67  Version 1.1 
  27 April 2020  non-cancer pain in patients with comorbid substance use  disorder. Pain 
2011;152:488 -97. 
23. Dersh J, Gatchel RJ, Polatin P, Mayer T. Prevalence  of Psychiatric 
Disorders in Patients With Chronic Work -Related Musculoskeletal Pain Disability. 
Journal of Occupational & Environmental Medicine 20 02;44:459.  
24. Zvolensky MJ, McMillan K, Gonzalez A, Asmundson GJ. Chronic pain and 
cigarette smoking and nicotine dependence among a r epresentative sample of 
adults. Nicotine & Tobacco Research 2009:ntp153.  
25. Von Korff M, Crane P, Lane M, et al. Chronic spinal  pain and physical -
mental comorbidity in the United States: results fr om the national comorbidity 
survey replication. Pain 2005;113:331 -9. 
26. Seal K, Shi Y, Cohen G, et al. Association of menta l health disorders with 
prescription opioids and high -risk opioid use in US veterans of Iraq and 
Afghanistan. JAMA: the Journal of the American Medi cal Association 
2012;307:940 -7. 
27. Jacobson IG, Ryan MAK, Hooper TI, et al. Alcohol Us e and Alcohol -Related 
Problems Before and After Military Combat Deploymen t. Jama 2008;300:663 -75. 
28. Milliken CS, Auchterlonie JL, Hoge CW. Longitudinal  Assessment of Mental 
Health Problems Among Active and Reserve Component Soldiers Returning From 
the Iraq War. Jama 2007;298:2141 -8. 
29. Substance Use Disorders in the U.S. Armed Forces: T he National 
Academies Press; 2012.  
30. Wilk JE, Bliese PD, Kim PY, Thomas JL, McGurk D, Ho ge CW. Relationship 
of combat experiences to alcohol misuse among U.S. soldiers returning from the 
Iraq war. Drug and Alcohol Dependence 2010;108:115 -21. 
31. Parry -Jones BL, Vaughan FL, Miles Cox W, Parry -Jones BL, Vaughan FL. 
Traumatic brain injury and substance misuse: a syst ematic review of prevalence 
and outcomes research (1994 -2004). Neuropsychological Rehabilitation 
2006;16:537 -60. 
32. Dunn AS, Julian T, Formolo LR, Green BN, Chicoine D R. Preliminary 
analysis of posttraumatic stress disorder screening  within specialty clinic setting 
for OIF/OEF veterans seeking care for neck or back pain. Journal of Rehabilitation 
Research & Development 2011;48:493 -502. 
33. Erbes CR, Curry, K.T, Leskela, J. Treatment present ation and adherence of 
Iraq/Afghanistan era veterans in outpatient care fo r posttraumatic stress disorder. 
Psychological Services 2009;6:175 -83. 
34. Morasco BJ, Corson K, Turk DC, Dobscha SK. Associat ion between 
substance use disorder status and pain -related function following 12 months of 
treatment in primary care patients with musculoskel etal pain. J Pain 2011;12:352 -
9. 
35. Trafton JA, Oliva EM, Horst DA, Minkel JD, Humphrey s K. Treatment needs 
associated with pain in substance use disorder pati ents: implications for 
concurrent treatment. Drug Alcohol Depend 2004;73:2 3-31. 
36. Arout CA, Edens E, Petrakis IL, Sofuoglu M. Targeti ng opioid -induced 
hyperalgesia in clinical treatment: neurobiological  considerations. CNS drugs 
2015;29:465 -86. 
Study Product Guidelines and Considerations  61 of 67  Version 1.1 
  27 April 2020  37. Burma NE, Bonin RP, Leduc -Pessah H, et al. Blocking microglial pannexin -
1 channels alleviates morphine withdrawal in rodent s. Nat Med 2017.  
38. Drdla R, Gassner M, Gingl E, Sandkuhler J. Inductio n of synaptic long -term 
potentiation after opioid withdrawal. Science 2009; 325:207 -10. 
39. Sayer NA, Spoont M, Nelson DB. Post -traumatic stress disorder claims 
from the viewpoint of veterans service officers. Mi l Med 2005;170:867 -70. 
40. Veterans Benefits Administration. Annual Benefits R eport Fiscal Year 2015. 
2016.  
41. Strasburger LH, Gutheil TG, Brodsky A. On wearing t wo hats: role conflict 
in serving as both psychotherapist and expert witne ss. American Journal of 
Psychiatry 1997;154:448 -56. 
42. House Committee on Veterans' Affairs. 2007. (Access ed May 23, 2007, 2007, 
at http://veterans.house.gov/hearings/schedule110/mar0 7/03-13-07/3-13-
07bilmes.shtml .) 
43. Prepared Statement of Karen H. Seal, M.D., MPH, Dep artment of Medicine 
and Psychiatry, San Francisco Department of Veterans Af fairs Medical Center, 
Veterans Health Administration, U.S. Department of Veterans Affairs.  House 
Committee on Veterans Affairs. Washington DC2011.  
44. Rosen MI. Compensation examinations for PTSD --an opportunity for 
treatment? Journal of Rehabilitation Research & Dev elopment 2010;47:xv -xxii. 
45. Miller WR, Rollnick S, eds. Motivational interviewi ng: Helping people 
change. 3rd ed. New York: Guilford Press; 2012.  
46. Magill M, Gaume J, Apodaca TR, et al. The technical  hypothesis of 
motivational interviewing: A meta -analysis of MI’s key causal model. Journal of 
Consulting and Clinical Psychology 2014;82:973 -83. 
47. Lundahl B, Moleni T, Burke BL, et al. Motivational interviewing in medical 
care settings: a systematic review and meta -analysis of randomized controlled 
trials. Patient education and counseling 2013;93:15 7-68. 
48. Lundahl BW, Kunz C, Brownell C, Tollefson D, Burke BL. A meta -analysis 
of motivational interviewing: Twenty -five years of empirical studies. Research on 
Social Work Practice 2010;20:137 -60. 
49. VanBuskirk KA, Wetherell JL. Motivational interview ing with primary care 
populations: a systematic review and meta -analysis. Journal of Behavioral 
Medicine 2014;37:768 -80. 
50. Hasin DS, Aharonovich E, O'Leary A, et al. Reducing  heavy drinking in HIV 
primary care: a randomized trial of brief interventi on, with and without 
technological enhancement. Addiction 2013;108:1230 -40. 
51. Lovejoy TI. Telephone -delivered motivational interviewing targeting sexua l 
risk behavior reduces depression, anxiety, and stre ss in HIV -positive older adults. 
Ann Behav Med 2012;44:416 -21. 
52. Rutledge SE, Roffman RA, Mahoney C, Picciano JF, Be rghuis JP, 
Kalichman SC. Motivational enhancement counseling s trategies in delivering a 
telephone -based brief HIV prevention intervention. Clinical S ocial Work Journal 
2001;29:291 -306. 
Study Product Guidelines and Considerations  62 of 67  Version 1.1 
  27 April 2020  53. McKay JR, Lynch KG, Shepard DS, Pettinati HN. The e ffectiveness of 
telephone -based continuing care for alcohol and cocaine depen dence - 24-month 
outcomes. Archives of General Psychiatry 2005;62:19 9-207. 
54. Bischof G, Grothues JM, Reinhardt S, Meyer C, John U, Rumpf HJ. 
Evaluation of a telephone -based stepped care intervention for alcohol -related 
disorders: a randomized controlled trial. Drug & Alc ohol Dependence 
2008;93:244 -51. 
55. Borsari B, Short EE, Mastroleo NR, et al. Phone -delivered brief motivational 
interventions for mandated college students deliver ed during the summer 
months. J Subst Abuse Treat 2014;46:592 -6. 
56. Stockl KM, Shin JS, Gong S, Harada A, Solow BK, Lew  HC. Improving 
patient self -management of multiple sclerosis through a disease therapy 
management program. The American journal of managed  care 2010;16:139 -44. 
57. Seal KH, Abadjian L, McCamish N, Shi Y, Tarasovsky G, Weingardt K. A 
randomized controlled trial of telephone motivation al interviewing to enhance 
mental health treatment engagement in Iraq and Afgh anistan veterans. Gen Hosp 
Psychiatry 2012;34:450 -9. 
58. Friedrich M, Gittler G, Halberstadt Y, Cermak T, He iller I. Combined exercise 
and motivation program: effect on the compliance an d level of disability of 
patients with chronic low back pain: a randomized co ntrolled trial. Archives of 
physical medicine and rehabilitation 1998;79:475 -87. 
59. Habib S, Morrissey S, Helmes E. Preparing for pain management: A pilot 
study to enhance engagement. The Journal of Pain 20 05;6:48 -54. 
60. Ballantyne J, Tauben DJ. Expert Decision Making on Opioid Treatment: 
Oxford University Press; 2013.  
61. Stacey D, Hawker G, Dervin G, et al. Management of Chronic Pain: 
Improving shared decision making in osteoarthritis.  BMJ 2008;336:954 -5. 
62. Sullivan MD, Leigh J, Gaster B. Brief report: Train ing internists in shared 
decision making about chronic opioid treatment for noncancer pain. Journal of 
General Internal Medicine 2006;21:360 -2. 
63. Nicolaidis C. Police Officer, Deal -Maker, or Health Care Provider? Moving to 
a Patient -Centered Framework for Chronic Opioid Management. P ain Medicine 
2011;12:890 -7. 
64. VHA National Center for Health Promotion and Diseas e Prevention. 
Motivational Interviewing for PACT Clinicians. In: System VHAEE, ed.2013.  
65. Alperstein D, Sharpe L. The efficacy of motivationa l interviewing in adults 
with chronic pain: A meta -analysis and systematic review. The Journal of Pain  
2016;17:393 -403. 
66. Babor TF, Biddle -Higgins, T.C. Brief Intervention For Hazardous and 
Harmful Drinking A Manual for Use in Primary Care. World Health Organization 
Department of Mental Health and Substance Abuse; 20 01. 
67. Babor TF, McRee BG, Kassebaum PA, et al. Screening,  Brief Intervention, 
and Referral to Treatment (SBIRT): toward a public health approach to the 
management of substance abuse. Substance Abuse 2007 ;28:7 -30. 
Study Product Guidelines and Considerations  63 of 67  Version 1.1 
  27 April 2020  68. Bertholet N, Daeppen J -B, Wietlisbach V, Fleming M, Burnand B. Reduction 
of alcohol consumption by brief alcohol interventio n in primary care: systematic 
review and meta -analysis. Archives of Internal Medicine 2005;165:98 6-95. 
69. Whitlock EP, Polen MR, Green CA, Orleans T, Klein J . Behavioral 
counseling interventions in primary care to reduce risky/harmful alcohol use by 
adults: a summary of the evidence for the US Preven tive Services Task Force. 
Annals of Internal Medicine 200 4;140:557 -68. 
70. Stead LF, Bergson G, Lancaster T. Physician advice for smoking 
cessation.[update of Cochrane Database Syst Rev. 20 04;(4):CD000165; PMID: 
15494989]. Cochrane Database Syst Rev 2008:CD000165 . 
71. Hettema JE, Hendricks PS. Motivational interviewing  for smoking 
cessation: a meta -analytic review. American Psychological Association ; 2010.  
72. Lai DT, Cahill K, Qin Y, Tang JL. Motivational inte rviewing for smoking 
cessation. The Cochrane Library 2010.  
73. Roy-Byrne P, Bumgardner K, Krupski A, et al. Brief inte rvention for 
problem drug use in safety -net primary care settings: a randomized clinical tri al. 
Jama 2014;312:492 -501. 
74. Saitz R, Palfai TP, Cheng DM, et al. Screening and b rief intervention for 
drug use in primary care: the ASPIRE randomized clin ical trial. Jama 
2014;312:502 -13. 
75. Moyer A, Finney JW, Swearingen CE, Vergun P. Brief interventions for 
alcohol problems: a meta -analytic review of controlled investigations in 
treatment -seeking and non -treatment -seeking populations. Addiction 
2002;97:279 -92. 
76. Saitz R. Alcohol screening and brief intervention i n primary care: Absence 
of evidence for efficacy in people with dependence or very heavy drinking. Drug 
Alcohol Rev 2010;29:631 -40. 
77. Bond GR, Drake RE, Becker DR. An Update on Randomiz ed Controlled 
Trials of Evidence -Based Supported Employment. Psychiatric Rehabilitat ion 
Journal 2008;31:280 -90. 
78. Frank JW, Carey EP, Fagan KM, et al. Evaluation of a telementoring 
intervention for pain management in the Veterans He alth Administration. Pain 
Med 2015;16:1090 -100. 
79. Pugh MJ, Leykum LK, Lanham HJ, et al. Implementatio n of the epilepsy 
center of excellence to improve access to and quali ty of care –protocol for a 
mixed methods study. Implementation Science 2014;9: 44. 
80. Switzer JA, Demaerschalk BM, Xie J, Fan L, Villa KF,  Wu EQ. Cost -
effectiveness of hub -and-spoke telestroke networks for the management of acu te 
ischemic stroke from the hospitals’ perspectives. C irculation: Cardiovascular 
Quality and Outcomes 2013;6:18 -26. 
81. Demaerschalk BM, Switzer JA, Xie J, Fan L, Villa KF,  Wu EQ. Cost utility of 
hub-and-spoke telestroke networks from societal perspective . The American 
journal of managed care 2013;19:976 -85. 
82. Gittell JH. Relational coordination: Guidelines for  theory, measurement and 
analysis. Waltham, MA: Brandeis University 2011.  
Study Product Guidelines and Considerations  64 of 67  Version 1.1 
  27 April 2020  83. Gittell JH, Fairfield KM, Bierbaum B, et al. Impact  of relational coordination 
on quality of care, postoperative pain and function ing, and length of stay: a nine -
hospital study of surgical patients. Medical care 2 000;38:807 -19. 
84. Gittell JH, Weiss L. Coordination networks within a nd across 
organizations: A multi ‐level Framework. Journal of Management Studies 
2004;41:127 -53. 
85. Hoffer Gittell J. Coordinating mechanisms in care p rovider groups: 
Relational coordination as a mediator and input unc ertainty as a moderator of 
performance effects. Management Science 2002;48:140 8-26. 
86. McDaniel Jr RR, Lanham HJ, Anderson RA. Implication s of complex 
adaptive systems theory for the design of research on health care organizations. 
Health care management review 2009;34:191.  
87. D’Onofrio G, O’Connor PG, Pantalon MV, et al. Emerg ency department –
initiated buprenorphine/naloxone treatment for opio id dependence: A randomized 
clinical trial. JAMA 2015;313:1636 -44. 
88. Redd D, Shaoa Y, Yang J, Divita G, Zeng -Treitler Q. Automated Learning of 
Temporal Expressions. Stud Health Technol Inform 20 15;216:639 -42. 
89. Breiman L. Stacked regressions. Machine Learning 19 96;24:49 -64. 
90. Stout RL, Wirtz PW, Carbonari JP, Del Boca FK. Ensu ring balanced 
distribution of prognostic factors in treatment out come research. Journal of 
Studies on Alcohol Supplement 1994;12:70 -5. 
91. Chou R, Qaseem A, Snow V, et al. Diagnosis and trea tment of low back 
pain: a joint clinical practice guideline from the American College of Physicians 
and the American Pain Society. Ann Intern Med 2007; 147:478 -91. 
92. Dorflinger L, Kerns R, Auerbach S. Providers' roles  in enhancing patients' 
adherence to pain self management. Behav Med Pract Policy Res 2013;3:39 -46. 
93. Longabaugh R, Woolard RE, Nirenberg TD, et al. Eval uating the effects of a 
brief motivational intervention for injured drinker s in the emergency department. 
Journal of Studies on Alcohol 2001;62:806 -16. 
94. Brown RL, Saunders LA, Bobula JA, Mundt MP, Koch PE . Randomized -
controlled trial of a telephone and mail interventi on for alcohol use disorders: 
three -month drinking outcomes. Alcohol Clin Exp Res 2007; 31:1372 -9. 
95. Karlin BE, Cross G. From the laboratory to the ther apy room: national 
dissemination and implementation of evidence -based psychotherapies in the US 
Department of Veterans Affairs Health Care System. American Psychologist 
2014;69:19.  
96. Martino S, Ball SA, Nich C, Frankforter TL, Carroll  KM. Community program 
therapist adherence and competence in motivational enhancement therapy. Drug 
Alcohol Depend 2008;96:37 -48. 
97. Schwalbe CS, Oh HY, Zweben A. Sustaining motivation al interviewing: A 
meta ‐analysis of training studies. Addiction 2014;109:12 87-94. 
98. Rounsaville BJ, Carroll KM, Onken LS. A stage model  of behavioral 
therapies research: Getting started and moving on f rom stage I. Clinical 
Psychology: Science and Practice 2001;8:133 -42. 
Study Product Guidelines and Considerations  65 of 67  Version 1.1 
  27 April 2020  99. Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragma tic–explanatory 
continuum indicator summary (PRECIS): a tool to hel p trial designers. Journal of 
clinical epidemiology 2009;62:464 -75. 
100. Gibbons CJ, Carroll KM, Ball SA, Nich C, Frankforte r TL, Martino S. 
Community program therapist adherence and competenc e in a motivational 
interviewing assessment intake session. The America n journal of drug and 
alcohol abuse 2010;36:342 -9. 
101. Santa Ana EJ, Carroll KM, Añez L, et al. Evaluating  motivational 
enhancement therapy adherence and competence among Spanish -speaking 
therapists. Drug and alcohol dependence 2009;103:44 -51. 
102. Ball SA, Martino S, Nich C, et al. Site matters: m ultisite randomized trial of 
motivational enhancement therapy in community drug abuse clinics. Journal of 
Consulting & Clinical Psychology 2007;75:556 -67. 
103. Carroll KM, Ball SA, Nich C, et al. Motivational in terviewing to improve 
treatment engagement and outcome in individuals see king treatment for 
substance abuse: a multisite effectiveness study. D rug Alcohol Depend 
2006;81:301 -12. 
104. Carroll KM, Martino S, Ball SA, et al. A multisite randomized effectiveness 
trial of motivational enhancement therapy for Spani sh-speaking substance users. 
Journal of consulting and clinical psychology 2009; 77:993.  
105. Martino S, Paris M, Añez L, et al. The effectivenes s and cost of clinical 
supervision for motivational interviewing: A random ized controlled trial. Journal 
of Substance Abuse Treatment 2016;68:11 -23. 
106. Martino S, Ball SA, Nich C, Canning -Ball M, Rounsaville BJ, Carroll KM. 
Teaching community program clinicians motivational interviewing using expert 
and train -the-trainer strategies. Addiction 2011;106:428 -41. 
107. Hoge CW, McGurk D, Thomas JL, Cox AL, Engel CC, Cas tro CA. Mild 
traumatic brain injury in US soldiers returning fro m Iraq. New England journal of 
medicine 2008;358:453 -63. 
108. Vanderploeg RD, Belanger HG, Curtiss G. Mild trauma tic brain injury and 
posttraumatic stress disorder and their association s with health symptoms. 
Archives of physical medicine and rehabilitation 20 09;90:1084 -93. 
109. Hoge CW, Auchterlonie JL, Milliken CS. Mental healt h problems, use of 
mental health services, and attrition from military  service after returning from 
deployment to Iraq or Afghanistan. Jama 2006;295:10 23-32. 
110. Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI , Koffman RL. 
Combat duty in Iraq and Afghanistan, mental health problems, and barriers to 
care. New England Journal of Medicine 2004;351:13 -22. 
111. Cleeland CS, Ryan KM. Pain assessment: global use o f the Brief Pain 
Inventory. Annals of the Academy of Medicine, Singa pore 1994;23:129 -38. 
112. Kroenke K, Bair MJ, Damush TM, et al. Optimized anti depressant therapy 
and pain self -management in primary care patients with depression  and 
musculoskeletal pain: a randomized controlled trial.  JAMA 2009;301:2099 -110. 
113. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome  measures for chronic 
pain clinical trials: IMMPACT recommendations. Pain  2005;113:9 -19. 
Study Product Guidelines and Considerations  66 of 67  Version 1.1 
  27 April 2020  114. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpretin g the clinical 
importance of treatment outcomes in chronic pain cl inical trials: IMMPACT 
recommendations. The journal of pain : official jou rnal of the American Pain 
Society 2008;9:105 -21. 
115. Jensen M, Karoly P. Self -report scales and procedures for assessing pain 
in adults. In: Turk D, R M, eds. Handbook of Pain A ssessment. New York: Guilford 
Press; 2001:15 -34. 
116. Goulet JL, Brandt C, Crystal S, et al. Agreement Be tween Electronic 
Medical Record -based and Self -Administered Pain Numeric Rating Scale: Clinical 
and Research Implications. Medical care 2013;51:245 -50. 
117. Krebs EE, Lorenz KA, Bair MJ, et al. Development an d Initial Validation of 
the PEG, a Three -item Scale Assessing Pain Intensity and Interferenc e. Journal of 
General Internal Medicine 2009;24:733 -8. 
118. Edelman EJ, Gordon K, Becker W, et al. Receipt of O pioid Analgesics by 
HIV-Infected and Uninfected Patients. Journal of Genera l Internal Medicine 
2013;28:82 -90. 
119. Organization WH. The Alcohol, Smoking and Substance  Involvement 
Screening Test (ASSIST) Manual for use in primary c are. 2010.  
120. WHO Assist Working Group. The Alcohol, Smoking and Substance 
Involvement Screening Test (ASSIST): development, r eliability and feasibility. 
Addiction 2002;97:1183 -94. 
121. Humeniuk R, Ali R, Babor TF, et al. Validation of t he Alcohol, Smoking And 
Substance Involvement Screening Test (ASSIST). Addi ction 2008;103:1039 -47. 
122. The ASSIST project - Alcohol, Smoking and Substance Involvement 
Screening Test. (Accessed February 21, 2017, 2017, at 
http://www.who.int/substance_abuse/activities/assis t/en/.) 
123. Potter J, Prather K, Kropp F, et al. A method to di agnose opioid 
dependence resulting from heroin versus prescriptio n opioids using the 
Composite International Diagnostic Interview. Conte mporary clinical trials 
2010;31:185 -8. 
124. Robins LN, Wing J, Wittchen HU, et al. The Composit e International 
Diagnostic Interview. An epidemiologic Instrument s uitable for use in conjunction 
with different diagnostic systems and in different cultures. Arch Gen Psychiatry 
1988;45:1069 -77. 
125. Weiss RD, Potter JS, Provost SE, et al. A multi -site, two -phase, Prescription 
Opioid Addiction Treatment Study (POATS): Rationale , design, and methodology. 
Contemporary Clinical Trials 2010;31:189 -99. 
126. Jones J, Jones M, Plate C, Lewis D. The Detection o f THCA Using 2 -
Dimensional Gas Chromatography -Tandem Mass Spectrometry in Human 
Fingernail Clippings: Method Validation and Compari son with Head Hair. 
American Journal of Analytical Chemistry 2013;Vol .04No.10:8.  
127. Berger L, Fendrich M, Jones J, Fuhrmann D, Plate C,  Lewis D. Ethyl 
glucuronide in hair and fingernails as a long -term alcohol biomarker. Addiction 
2014;109:425 -31. 
Study Product Guidelines and Considerations  67 of 67  Version 1.1 
  27 April 2020  128. Bradley KA, DeBenedetti AF, Volk RJ, et al. AUDIT -C as a brief screen for 
alcohol misuse in primary care. Alcoholism: Clinica l & Experimental Research 
2007;31:1208 -17. 
129. Kroencke K, Spitzer R, Williams J. The PHQ -9: validity of a brief depression 
severity measure [Electronic version]. Journal of G eneral Internal Medicine 
2001;16:606 -13. 
130. Herdman M, Gudex C, Lloyd A, et al. Development and  preliminary testing 
of the new five -level version of EQ -5D (EQ -5D-5L). Qual Life Res 2011;20:1727 -36. 
131. Ondersma SJ, Svikis DS, Schuster CR, Ondersma SJ, S vikis DS, Schuster 
CR. Computer -based brief intervention a randomized trial with pos tpartum 
women. American Journal of Preventive Medicine 2007 ;32:231 -8. 
132. LaBrie JW, Quinlan T, Schiffman JE, et al. Performa nce of alcohol and safer 
sex change rulers compared with readiness to change  questionnaires. 
Psychology of Addictive Behaviors 2005;19:112 -5. 
133. Assanangkornchai S, Nima P, McNeil EB, Edwards JG. Comparative trial of 
the WHO ASSIST -linked brief intervention and simple advice for sub stance abuse 
in primary care. Asian J Psychiatr 2015;18:75 -80. 
 
 
15. SUPPLEMENTS/APPENDICES  
I. Informed Consent Form Template  
VA Central IRB reviewed and approved Information Sheet  (v. 11/8/18)  
VA Central IRB reviewed and approved Phone Script (v . 11/8/18)  
 
II. VA Central IRB reviewed and approved Protocol ( v.11/8/18)  
 
 
 